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SOMATOSTATIN RECEPTOR 2 REGULATION BY C-TERMINAL MOTIFS AND
PDZ DOMAIN PROTEINS

Courtney Olsen, B.A.
Advisory Professor: Agnes Schonbrunn, Ph.D.

Somatostatin receptor 2 (sst2) is a Gi-coupled G-protein coupled receptor that
mediates many of somatostatin’s neuroendocrine actions. Sst2 is a clinically
important GPCR as it is the drug target of somatostatin analogs such as octreotide,
lanreotide, and pasireotide. Treatment with these agonists is the main medical
approach to controlling excessive hormone secretion from neuroendocrine tumors.
Activation of sst2 decreases hormone secretion by inhibiting cAMP production and
decreasing intracellular calcium concentrations. In addition, treatment with
somatostatin analogs has been shown to decrease tumor growth. Unfortunately,
many patients will fail to respond to somatostatin analogs despite sst2 being present
on their tumors. Understanding the signaling, trafficking, and regulation of sst2 is
crucial to determine why many patients fail to respond to these agonists. As
Postsynaptic density protein/Discs large-1/Zona occludens-1 (PDZ) domain
interactions often regulate the trafficking and signaling potential of other GPCRs, we
examined the role of the sst2 PDZ ligand and additional C-terminal residues in
controlling its intracellular trafficking, signaling, and regulation. We determined that
sst2 traffics from early endosomes to late endosomes and then on to the trans-golgi
network (TGN). Trafficking from late endosomes to the TGN is dependent upon an
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intact C-terminal tail and the retromer complex of endosomal coat proteins.
Additionally, removing either 3 or 10 C-terminal amino acids from sst2 alters the
pathway through which sst2 recycles to the plasma membrane. We also determined
that the expression of SHANK3, a PDZ domain containing protein, could alter the
plasma membrane expression of sst2 indicating an important role in sst2 regulation.
Overall, our results indicate that sst2 trafficking and regulation depends upon an
intact PDZ ligand and C-terminal tail.
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Chapter 1
Introduction

1.1 Somatostatin Receptors
The family of somatostatin receptors was originally discovered in pituitary
cells and was subsequently found to be present throughout the endocrine,
neuroendocrine, and gastrointestinal (GI) system and act to negatively regulate
hormone secretion(1-4). Additionally, they are present in the central and peripheral
nervous systems and act to regulate cognitive, motor, and sensory functions as well
as pain transmission(5, 6). Physiologically, they play important roles in inhibiting a
wide range of hormone secretion including growth hormone, insulin, and glucagon.
These receptors also inhibit GI and pancreatic exocrine secretion(2, 3, 7).
The family of somatostatin receptors consists of five members, part of the
larger family of G protein coupled receptors (GPCRs), and exert their actions mainly
through coupling to Gi and Go proteins, members of the family of heterotrimeric
guanine-nucleotide binding proteins (G-proteins), to inhibit cyclic adenosine
monophosphate (cAMP)(8-11). Somatostatin receptors have two endogenous
ligands that exist as cyclic peptide products, Somatostatin 14 (SS14) and
Somatostatin 28 (SS28) generated from a 116 amino acid precursor product. Both
ligands bind to all 5 family members with similar high affinity(3). Along with their
importance in endogenous physiological functions, somatostatin receptors play an
important role clinically as they are highly expressed on the surface of many
neuroendocrine tumors (NETs)(1, 12-14). Somatostatin analogs, which act by
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activating somatostatin receptors, were developed to control the high levels of
hormones secreted from these tumors(15). Octreotide is the main drug in this class
and acts by activating sst2 to both inhibit hormone secretion and slow tumor growth
and as such sst2 is a crucial receptor for the overall treatment of NETs(2, 16-18).

1.2 Neuroendocrine Tumors (NETs)
NETs are tumors that arise from endocrine tissues such as pituitary and
pancreas as well as the diffuse neuroendocrine system(19). These tumors can be
functional, meaning that they secrete hormones, or non-functional, and benign and
malignant tumors fall into both categories. The cell type of origin determines the
hormone secreted and over 15 neuroendocrine cell types secreting different
hormones have been identified(20-22). One of the most difficult aspects of managing
these tumors is the hormonal hyper-secretion leading to different endocrine
syndromes (Fig 1)(19, 23). Although certain NETs are more likely to be malignant,
tumors arising from any of the different cell types can be either benign or malignant
and treatment varies depending on the aggressiveness of the tumor(19, 22, 24, 25).
NETs are grouped into 3 basics types, those that arise from the pituitary,
those that arise from the endocrine pancreas, and those that occur in the diffuse
gastrointestinal and bronchial neuroendocrine tissue. Pituitary tumors can secrete
growth hormone (GH), adrenocorticotrophic hormone (ACTH), prolactin, or
thyrotropin stimulating hormone (TSH)(26, 27). Those from the endocrine pancreas
can secrete insulin, glucagon, gastrin, vasoactive intestinal peptide (VIP), or
somatostatin(28). GI and bronchial neuroendocrine tumors tend to secrete serotonin
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and other vasoactive hormones including histamine, bradykinin, and other members
of the tachykinin family of peptides(29).

Figure 1. Neuroendocrine Tumors. The main sites for neuroendocrine tumors
include the pituitary, bronchial tree, the pancreas, and the gastrointestinal
system. These tumors can be nonfunctional or functional depending on if they
secrete hormones. Functional tumors can secrete a variety of hormones
depending on their tissue of origin as listed above and can cause symptoms
ranging from debilitating to deadly.
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NETs can be sporadic or associated with a genetic syndrome and numerous
drivers of tumorigenesis have been implicated. Mutations in GNAS and mutations
and amplifications of GPR101, a Gs-coupled GPCR, can lead to somatotroph
tumors implicating cAMP as a driver of both tumorigenesis and GH secretion(30,
31). Other mutations include those in AIP, MENIN, CDKN1B, PRKAR1A, and the
genes of the succinate dehydrogenase family (SDH)(32). Patients with
neurofibromatosis type 1 and tuberous sclerosis are also predisposed to developing
NETs, implicating the PI3K/AKT/mTOR pathway in tumorigenesis(33). Tumors
driven by these various mutations differ in their response to somatostatin analogs
including octreotide(16, 34, 35). How these mutations change the response to
somatostatin analogs is not completely clear, although there are some mechanistic
explanations depending on the mutation. For example, treatment with octreotide
actually increases expression of AIP leading to a poor response to treatment(35,
36). Tumors with identifiable drivers and those that are part of genetic syndromes
are a small percentage of the total population of neuroendocrine tumors(32). The
drivers of neuroendocrine tumors and how they may change response to treatment,
especially to somatostatin analogs, is still poorly understood.
Almost all neuroendocrine tumors, both functional and non-functional,
express sst2 at high levels on the cells surface(37, 38). Some also express sst5, as
well as the other somatostatin receptor subtypes(39). This is generally dependent on
the tumor type (although not always the case), as ACTH secreting tumors of the
pituitary, and insulinomas of the pancreas are more likely to express higher levels of
sst5 versus GH-secreting pituitary tumors that are more likely to express high levels
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of sst2(40). These patterns of expression help to guide appropriate therapies for the
various different NETs.	
  	
  
	
  
1.3 Somatostatin Analogs (SA)	
  
As the half-life of SS14 and SS28 in circulation is about 1-3 min, stable
peptides have been developed to target the family of somatostatin receptors for the
treatment of NETs(18). Octreotide is the main medical treatment available to control
hormone hyper-secretion from NETs. The mechanism of action is through binding to
and activating sst2 specifically(5, 41). Octreotide is safe and effective for many
patients, however different tumor types show different patterns of resistance.
Patients with GH-secreting tumors causing acromegaly or gigantism tend to either
respond or not after the initial trial of drug and about 40-50% of patients will fail to
control their hormone hyper-secretion with octreotide(16). The mechanisms that
regulate this response are unclear. The response to octreotide does not correlate
with receptor mRNA levels and mutations within sst2 are rarely found within pituitary
tumors(16, 38). Given these findings, it is likely that the resistance is derived from
the cellular environment, meaning that either the regulation of sst2 or its ability to
engage with its downstream signaling transduction machinery is altered. This is in
contrast to patients with GI and pancreatic NETs that tend to lose responsiveness to
treatment over months or years of treatment(2, 16, 42). Given the long period before
resistance develops, the mechanism is more likely dependent on expression
changes of sst2 or its effectors as tumors grow and develop(2).
Additionally, lanreotide is a clinically used SA that is also an sst2 specific
agonist(43). In addition to the inhibition of hormone secretion, both octreotide and
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lanreotide have been shown to have anti-tumor effects separate from their effects on
hormone secretion(44, 45). This has been shown in a series of clinical trials
demonstrating that SAs can increase the time to progression for non-functioning
neuroendocrine tumors(44, 46). This effect has also been shown in preclinical
models and the mechanisms and signaling leading to these anti-tumor effects have
yet to be fully elucidated(47).
Recently, an additional SA, pasireotide, was approved for use in treatment
resistant acromegaly and Cushing’s disease. Unlike octreotide and lanreotide,
pasireotide, also referred to as SOM230, is not an sst2 specific agonist and will
activate both sst2 and sst5. Additionally, pasireotide acts as a biased agonist at sst2,
meaning that it does not activate the same set of pathways as the receptor’s
endogenous ligand, SS14(48, 49). In addition to the development of SAs for the
treatment of neuroendocrine tumors, radiolabeled octreotide compounds are used
for both diagnostic and therapeutic purposes in clinic. Radiolabeled octreotide allows
for accurate localization of NETs and peptide receptor radionuclide therapy (PRRT)
has recently become available as a treatment for sst2 positive NETs(50).

1.4 Somatostatin Receptor 2 (sst2) Signaling
Sst2 is a GPCR that primarily couples to Gi/Go proteins to inhibit adenylate
cyclase (AC)(8, 10, 51). The inhibition of AC and subsequent reduction of cAMP
levels is the main mechanism through which sst2 can inhibit hormone secretion(52).
Additionally, there are other cAMP-independent mechanisms through which sst2 can
inhibit hormone secretion. These have been most extensively studied in GH4C1
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cells. GH4C1 cells were derived from a spontaneous rat somatolactotroph pituitary
tumor and secrete GH and prolactin both at a basal level and after stimulation(53).
The activation of Gi/Go proteins by sst2 in GH4C1 cells can activate potassium
channels (such as G-protein gated inward rectifier) leading to membrane
hyperpolarization. The subsequent inhibition of voltage dependent calcium channels
due to membrane hyperpolarization causes a decrease in intracellular calcium(51,
54, 55). Reduction of either cAMP or intracellular Ca2+ will lead to a decrease in
hormone secretion, and together the effect is synergistic(55). The effect on K+
channels is pertussis toxin (PTX) sensitive, indicating the necessity of Gi/Go
proteins, and independent of the cAMP levels, as activation of sst2 still was able to
hyperpolarize the membrane even in the presence of a stable cAMP analog(54, 55).
Sst2 has also been shown to regulate calcium channels directly, through direct
inhibition, also in a PTX-dependent manner(55). These effects have been shown in
a variety of different neuroendocrine cells lines including: other pituitary somatotroph
cells lines such as GH12C1 and GH3 cells, AtT20 cells, a corticotroph cell line, as
well as BON cells, a pancreatic NET cell line, and several insulinoma cell lines
amongst others(48, 56-60). The inhibitory effects of sst2 on hormone secretion have
also been shown using human pituitary tumor samples and are well documented
clinically through the use of somatostatin analogs(61).
Activation of sst2 has long been shown to inhibit tumor growth through
several different mechanisms including the blockade of cell cycle progression,
indirect inhibition of the secretion of growth factors, and through the inhibition of
angiogenesis(2, 62). Sst2 has been shown to couple to phosphotyrosine
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phosphatases, including SHP-1, SHP-2, and PTPη as well as serine/threonine
phosphatases including PP2A and PP2B(63-66). Coupling to phosphotyrosine
phosphatases allows sst2 to regulate growth factor receptors and their downstream
effectors to regulate cell cycle progression and induce apoptosis. Sst2 has also been
shown to regulate the extracellular signal-regulated kinase/mitogen-activated protein
kinases pathway (ERK/MAPK) although the regulation is cell type specific(48).
Interestingly, the downstream consequences of the activation or inhibition of the
ERK/MAPK pathway is also cell type specific. For example, activation of ERK in
somatolactotroph cells will inhibit cells growth, opposite of the role ERK plays in
most tissues(67-69). Sst2 will activate the ERK pathway under certain conditions
and inhibit it under others. The activation or inhibition of the ERK/MAPK pathway is
also dependent upon the agonist used to stimulate sst2. Stimulation of sst2 in
Human Embryonic Kidney (HEK293) cells leads to a transient activation of ERK and
there is both a PTX-sensitive and PTX-insensitive component to the activation. The
activation of the ERK/MAPK pathway in other cells, such as AR42J cells, by sst2
has been shown to be through PTX-insensitive G-proteins such as G14. It is unclear
what the mechanism of PTX-insensitive ERK activation is in HEK293 cells as they
do not express G14(48). In addition to the differences seen in ERK activation in
different cell lines, sst2 also exhibits other cell specific effects such as the ability to
increase intracellular calcium in HEK293 cells versus inhibiting intracellular calcium
accumulation in somatotroph cells(48, 54, 55).

	
  

8	
  

sst2%
K+%

Ca2+%

AC%

K+%
Ca2+%

cAMP%%

Hormone%
Secre4on%

	
  
Figure 2: Sst2 signaling in somatolactotroph cells. Sst2 signaling has been best
characterized in somatolactotroph cell lines. Sst2 is a Gi/o coupled GPCR and acts
to inhibit cAMP. The decrease in cAMP leads to an inhibition of hormone secretion.
Additionally sst2 acts by activating potassium channels to hyperpolarize cells. This
leads to an inhibition of voltage gated ion channels, a decrease in intracellular
calcium, and the inhibition of growth hormone secretion. These pathways can act
independently to decrease secretion and are synergistic when activated together.
Additionally, sst2 can signal to addition pathways such as the ERK/MAPK pathway
and through phosphotyrosine phosphatases.
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1.4 Sst2 Regulation and Trafficking
Endocytosis of receptors and intracellular trafficking is a major mechanism of
GPCR regulation(70). Following internalization, GPCRs can either be recycled to the
plasma membrane or sorted into degradation pathways to be degraded either in
lysosomes or by the proteasome(71). Originally thought to regulate only the duration
of stimulation and subsequent resensitization of receptors, endocytosis has recently
been shown to also regulate the specific signaling profile activated by GPCRs (7275). In vivo trafficking of sst2 has been shown in several different NET tumor types
both by somatostatin receptor scintigraphy and through immunohistochemistry of
octreotide treated human tumor samples(76-78). Like other GPCRs, sst2 trafficking
is intricately regulated by numerous effectors including β-arrestin, kinases, and
phosphatases(66, 79, 80).
After stimulation with agonist, sst2 is rapidly phosphorylated, internalized, and
desensitized. This has been demonstrated in a variety of cell lines(76, 81, 82).
Stimulation with SS14 leads to rapid phosphorylation by G-protein receptor kinases
(GRK) at numerous sites in the C-terminal tail and third intracellular loop mainly
mediated by GRK2 and GRK3(83). Phosphorylation of sst2 has been shown to
influence its trafficking, as phosphorylation of the threonine cluster on the C-terminal
tail is required for β-arrestin recruitment and binding(79). Additionally,
phosphorylation of the serine cluster in the C-terminal tail is important for
desensitization(79). Sst2 has also been shown to be phosphorylated by PKC
although the functional consequences of PKC phosphorylation are still unclear(83).
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Phosphorylation of the threonine cluster in the C-terminal tail leads to β-arrestin
binding, the recruitment of AP1 and clathrin, and internalization into clathrin coated
pits in a dynamin-dependent manner(79, 80). Class A GPCRs transiently interact
with β-arrestin and class B GPCRs form stable complexes with β-arrestin during
endocytosis. Both β-arrestin1 and β-arrestin2 are recruited to the plasma membrane
after stimulation of sst2 and forms a stable complex with sst2 during internalization
indicating that sst2 belongs to the class B subgroup. After endocytosis, sst2
internalizes into early endosomes, however the trafficking pathway past this first step
has not been well described(84). Trafficking of sst2 to the trans-golgi network (TGN)
has been shown in both HEK293 and neuronal cell lines although neither the
mechanism for how sst2 traffics to the TGN nor the functional consequence of this
pathway has been demonstrated(82-85). Sst2 also can rapidly recycle to the plasma
membrane after the removal of agonist, although it was not known which pathways
the receptor recycles through or which proteins are required(Fig. 3)(80). Very little
degradation of sst2 is seen after stimulation, consistent with most of the receptors
returning to the plasma membrane after the removal of ligand(80). How sst2 traffics
through this pathway, whether sst2 can enter multiple intracellular trafficking
pathways, and which domains on sst2 are required for trafficking had not been
determined prior to this study.
While some of the phosphorylation sites in the C-terminal tail have been
shown to be involved in trafficking, little is known about how protein-protein binding
within the C-terminal tail regulates sst2 trafficking. Sst2 has a highly evolutionarily
conserved class I PDZ ligand at its C-terminal tail(7). PDZ ligands are protein-protein
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binding motifs and class I ligands are defined by having a serine or threonine in the 2 position followed by any amino acid and a hydrophobic amino at the C-terminal
position (S/T-X-Φ)(86). Class I PDZ ligands are present on numerous GPCRs and
are important regulators of receptor recycling, intracellular trafficking, and receptor
signaling through binding to PDZ domain containing proteins(86, 87). Although sst2
has been shown to bind to three PDZ domain containing proteins, SHANK1,
SHANK2, and PDZK1, nothing was known about the function of the sst2 PDZ
ligand(88-91).
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Figure 3: Sst2 intracellular trafficking. While sst2 has been shown to
internalize after stimulation with ligand and recycle to the plasma membrane, little
is known about its intracellular trafficking pathway. Sst2 has been shown to
internalize into early endosomes (EE), traffic to the trans-golgi network (TGN),
and recycle to the plasma membrane.
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1.5 GPCR Endocytic Trafficking
Endocytic trafficking is a major mechanism of GPCR regulation and in turn,
GPCR trafficking is regulated by numerous mechanisms. GPCRs exhibit sequencedependent recycling, meaning that they require specific cytoplasmic amino acids
sequences for proper intracellular trafficking(70, 92, 93). The sequences can bind to
cytoplasmic adapter proteins to direct their trafficking or can be modified including
through phosphorylation or ubiquitination to alter their intracellular fate(92, 94, 95).
The first step in trafficking occurs immediately after stimulation with ligand and
receptors are rapidly phosphorylated, can bind to β-arrestin, and are endocytosed in
clathrin-coated pits(93, 96). This process is the first step in endocytic sorting as
receptors can vary greatly in terms of their phosphorylation sites and β-arrestin
recruitment. Additionally, some receptors internalize via clathrin-independent
mechanisms(97, 98). After internalization, receptors are sorted along the endocytic
pathway and many internalize into early endosomes. The early endosome has been
shown to be a highly dynamic and regulated system that allows for sorting of diverse
cargos including numerous different GPCRs and other membrane receptors(71, 99101). From the early endosome, receptors can be trafficked back to the plasma
membrane, traffic through longer recycling pathways including trafficking through the
TGN, or be trafficked to lysosomes for subsequent degradation(102-104). A major
mechanism of endosomal regulation is through the action of Rab GTPases.
Rab GTPases are part of the family of small GTPase proteins and are major
regulators of endosomal dynamics(71, 105, 106). These proteins cycle on and off of
endosomes to help regulate membrane trafficking. Inactive Rab proteins are soluble
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and located diffusely in the cytosol bound by Rab GDP-dissociation inhibitors(104,
107). Whereas, active Rab proteins are located on specific endosomal populations
and intracellular organelles to regulate vesicular transportation. The various Rab
proteins allow for compartmentalization of the endocytic trafficking pathway. Rab5 is
located on early endosomes whereas other Rabs including Rab4 and Rab11
regulate recycling endosomes(71, 105). Rab4 regulates endosomal traffic back to
the plasma membrane from early endosomes and Rab11 regulates recycling from a
less well-defined perinuclear recycling compartment(108, 109). Two other wellcharacterized Rab proteins include Rab7, which functions to allow for vesicular
transport between the endocytic pathway and lysosomes, and Rab9 regulates
trafficking of cargo between late endosomes and the Golgi complex(110, 111).
Numerous GPCRs traffic through Rab containing endocytic compartments
depending on protein-protein binding and post-translational motifs. For examples,
the µ-opioid receptor (µOR) traffics through Rab4 or Rab11-positive endosomes
depending on its phosphorylation state. Only non-phosphorylated µOR can recycle
to the plasma membrane through Rab11-positive endosomes whereas
phosphorylated receptor recycles primarily in Rab4-positive endosomes(112).
Additionally, endosomal protein-protein interactions have been shown to alter the
endocytic fate of numerous receptors including β2AR, LHR, and PTHR1(70, 86).
While a receptor’s ability to traffic into different endosomal populations depending on
protein-protein interactions and post-translational modifications has been welldescribed, a more detailed understanding of the mechanisms of receptor sorting is
beginning to emerge. Receptors are sorted along each step of the endocytic
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pathway and detailed sorting occurs within microdomains on the endosome.
Differential sorting within these microdomains is sufficient to alter both the endocytic
fate of the receptor and alter its signaling(94, 101, 113, 114).
Sorting at the endosomes is a dynamic and highly regulated process.
Receptors can either be sorted into intraluminal vesicles to eventually be degraded
in lysosomes or can be sorted into specific endosomal domains to be further
trafficked along the endosomal pathway or to be returned to the plasma membrane.
This occurs in a coordinated fashion and depends upon the protein machinery
present at the endosome.
A major mechanism of endosomal sorting is through the retromer complex of
coat proteins, which is an evolutionarily conserved complex of endosomal proteins.
While the complex was originally discovered in yeast, mammalian cells have a highly
homologous complex composed of five proteins, SNX1/2, SNX5/6, Vps26, Vps29,
and Vps35, and acts to sort cargos from the late endosome to the trans-golgi
network during retrograde trafficking (115). The retromer complex has been shown
to be involved in the trafficking of other GPCRs including the β2-adrenergic receptor
(β2AR) and the parathyroid hormone receptor 1 (PTHR1) (75, 116). It also functions
to sort a wide variety of other protein cargos such as the cation-independent
mannose-6-phosphate receptor (CI-M6PR) and Wntless(117). The balance
between recycling and degradation is crucial to maintain specific plasma membrane
receptor levels. In fact, disruption of the retromer complex is associated with a
variety of diseases including Alzheimer’s and Parkinson’s disease and knockout of
the retromer subunits is embryonically lethal, indicating the critical role of the
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retromer in cellular homeostasis(118). Additionally, the retromer complex has been
shown to be crucial for the regulation of Wnt secretion and also for the coordination
of GPCR signaling at the endosome(119, 120). The retromer has been shown to be
a crucial regulator of receptor trafficking and therefore a major regulator of receptor
signaling.

1.6 PDZ Domain Proteins
PDZ proteins are named for a structural domain that is present on
postsynaptic density protein (PSD95), Drosophila disc large tumor suppressor
(DlgA), and zonula occludens-1 protein (ZO-1)(86, 87, 121). About 200-300 PDZ
proteins are in the mammalian genome and are cytoplasmic adaptor proteins that
allow for assembly of multi-protein signaling complexes(86). The PDZ domain itself
is composed of six β-sheets and two α-helices and the ligand binds between second
β-sheet and second α-helix and allows for a large flexibility in binding to different
ligands with a single PDZ domain being able to bind to potentially hundreds of PDZ
ligand containing proteins(122). This allows for intricate spatial and temporal control
of receptor signaling. PDZ domain containing proteins can contain single or multiple
PDZ domains along with other protein-protein binding motifs, allowing for the
production of large protein signaling complexes. Increasingly, PDZ domain
containing proteins have been shown to regulate numerous aspects of GPCR
signaling and trafficking. While there are now numerous examples in the literature,
the β2-adrenergic receptor (β2AR) was the first example of a GPCR function being
regulated by a PDZ domain protein. β2AR was shown to bind to NHERF1 to allow
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β2AR to regulate the NHE3 sodium-protein exchanger(123). PDZ proteins have
been shown to switch G-protein coupling, alter β-arrestin binding, tether receptors at
the plasma membrane, and bind to downstream signaling effectors such as protein
kinase A (PKA) and phospholipase C (PLC) amongst other functions(86). Binding to
PDZ domain proteins allows GPCRs to exert both receptor-specific and cell-specific
effects.

1.7 The Role of PDZ domain containing proteins in GPCR trafficking
Increasingly, GPCR trafficking has been shown to be regulated by numerous
elements including binding to cytoplasmic adaptor proteins. This regulation in turn
affects GPCR function. PDZ domain proteins can influence receptor trafficking
through tethering the receptor at the plasma membrane, directing receptors in early
endosomes or very early endosomes, and directing receptors into specific recycling
pathways(70, 86). β2AR was the first GPCR whose trafficking was shown to be
regulated by PDZ domain proteins. The PDZ ligand allowed β2AR to be sorted into a
recycling pathway to be returned to the plasma membrane after internalization(124).
Consistent with the hypothesis that receptors need to recycle through specific
pathways for resensitization, PDZ ligand dependent recycling of β2AR was also
shown to enhance the cAMP response after prolonged stimulation of β2AR(125). A
great deal of work has since been done on the role of the β2AR PDZ ligand in
receptor trafficking.
Type I PDZ ligands have since been shown to be sufficient for receptor
recycling by fusing the last 10 amino acids to a non-recycling receptor, the δ-opioid
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receptor (δOR)(126, 127). Normally, δOR is trafficked to lysosomes for degradation
after internalization, however its endocytic fate can be altered and the receptor can
be rerouted to the plasma membrane when the last 10 amino acids of β2AR are
fused to the receptor. This recycling is dependent upon an intact PDZ ligand as
adding the last 10 amino acids with the final C-terminal amino acid mutated to an
alanine to disrupt PDZ binding is not sufficient to change δOR to a recycling
receptor. Later the PDZ domain was shown to be required for β2AR to be localized
in specific endosomal tubules, which is required for both signaling and the endocytic
fate of the receptor. Similarly, the PDZ ligand of the β1-adernergic receptor (β1AR)
is also required for receptor recycling(128). β1AR binds to SAP97 through a PDZ
mediated interaction allowing the receptor to complex with AKAP79. This complex
allows for PKA mediated phosphorylation of a 3rd loop site that is also required for
recycling(128, 129).
Interestingly, some GPCRs can bind to multiple PDZ domain proteins that
have opposing effects on receptor function. For example, the serotonin 2C receptor
(5HT2CR) can bind to both PSD95, which promotes endocytosis and
desensitization, and MPP3, which tethers the receptor at the membrane and
promotes resensitization(130). Other GPCRs whose intracellular trafficking is
regulated by PDZ ligand-domain interactions include CXCR2 chemokine receptor,
which protects it from trafficking to lysosomes and subsequent degradation, the
luteinizing hormone receptor (LHR) whose PDZ ligand allows for trafficking into very
early endosomes (VEEs) and promotes recycling, and the thyrotropin stimulating
hormone receptor (TSHR) whose ligand allows for tethering at the plasma
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membrane and promoting recycling(131-133). PDZ ligand-domain interactions have
been shown to be crucial regulators of GPCR trafficking, regulation, and signaling.

1.8 SHANK Proteins
The SHANK family of proteins consists of three members, SHANK1,
SHANK2, and SHANK3, which are large synaptic scaffolding proteins(134). SHANK
proteins have been best studied in the central nervous system as they are present at
nearly all excitatory glutaminergic synapses(135). They play critical roles in
numerous neuronal processes including actin/cytoskeleton remodeling, AMPA
receptor endocytosis, synapse formation, glutaminergic transmission, and synaptic
plasticity. The role of SHANK proteins in human neuronal disease was first
recognized when SHANK3 loss was recognized as the cause of intellectual disability
in Phelan-McDermind Syndrome (PMS)(136). Since then, mutations, deletions, and
duplications of the three SHANK proteins have been found in numerous patients
with autism, schizophrenia, and bipolar disorder(137, 138).
All three SHANK proteins have the same basic structure with N-terminal
ankyrin repeats, an SH3 domain, a PDZ domain, a large proline rich region, and a Cterminal sterile alpha motif (SAM)(Fig 4)(139, 140). These various protein-protein
binding motifs allow all three SHANK proteins to bind to a large number of other
proteins, over 30 binding partners have been identified, and they act as major
organizers at the post-synaptic density. These binding proteins include ion channels,
GPCRs, other scaffolding proteins, enzymes, and cytoskeletal proteins. SHANK1,
SHANK2, and SHANK3 are highly homologous and indeed can bind to many of the
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same proteins(135). SHANK proteins are major organizers at the post-synaptic
density (PSD) and allow for receptors to be linked to their downstream protein
machinery for rapid signal transduction.

Figure 4: Structure of SHANK proteins. All three SHANK family members
contain the same basic structure consisting of ankyrin repeats (ANK), a src
homology 3 domain (SH3), a postsynaptic density protein (PSD95), Drosophila
disc large tumor suppressor (Dlg1), zonula occludens-1 protein (ZO-1) domain
(PDZ), a large proline rich region, and a sterile alpha motif (SAM). These
protein-protein domains allow for SHANK proteins to act as large molecular
scaffolds and act as regulators at the post-synaptic density and other cellular
microdomains.
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All three SHANK proteins show broad distribution throughout the brain but do
show different expression patterns and subcellular localizations(141, 142). The
degree of functional overlap between the three SHANK proteins is still unknown. All
three SHANK proteins are extensively spliced and regulated through multiple
intragenic promoters(139). Six intragenic promoters have been identified for
SHANK3 and although multiple different protein isoforms have been characterized, it
is possible that additional isoforms in various tissue types have yet to be
identified(143). Each SHANK3 isoform contains a unique set of protein-protein
binding domains likely allowing for each isoform to confer a specific function. It is
thought that the wide array of isoforms contributes to signaling specificity. Some of
the isoforms of SHANK proteins have been shown to have unique functions.
Interestingly, the SAM domain of SHANK2 and SHANK3 is required for synaptic
targeting, although this is not the case for SHANK1. The SAM domain also allows for
SHANK3 to scaffold to itself and is thought to be crucial for organization of the postsynaptic density. Additionally there is some clinical data suggesting that certain
isoforms play specific signaling roles, as patients with mutations in SHANK3 only
have these mutations in certain isoforms further suggesting that each isoform serves
a specific function that cannot be compensated for by alternative isoforms(144).
SHANK1 and SHANK2 have been shown to bind to sst2 through their PDZ
domains(88-90). They were initially identified as sst2 binding proteins using a yeast
2 hybrid screen with the C-terminal of sst2 as bait and a human brain cDNA library.
Although the group that identified these binding partners were not able to find a
function for this protein-protein binding, they concluded that SHANK2 is recruited to
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the plasma membrane in sst2 expressing cells after stimulation with SS14. Although,
a change in subcellular localization of SHANK2 was identified after stimulation with
SS14, no specific function altering sst2 signaling or regulation was identified. It is
likely that SHANK1, SHANK2, and SHANK3 have different effects on sst2 regulation
and signaling, allowing sst2 to exert context specific effects when activated.
Interestingly, SHANK2 and SHANK3 were also identified in rat pituitary cells,
specifically somatotrophs, indicating that SHANK proteins likely play a role in sst2
regulation in the pituitary(145). An important outstanding question is which isoforms
of SHANK2 and SHANK3 are present in the pituitary, as this would determine both
the possibility for these proteins to interact with sst2 in a PDZ dependent manner,
and would affect the specific regulatory effects they had on sst2. Of note, we
determined that SHANK expression varies between rat and human and while
SHANK2 and SHANK3 are expressed in rat pituitary, SHANK1 and SHANK3 are
present in human pituitary tissue.

1.9 Summary
Sst2 plays a crucial role in both the physiologic control of hormone secretion
as well as the treatment of pathologic hormone secretion from neuroendocrine
tumors. In addition to these roles, sst2 activation has well-established effects on cell
growth and proliferation, cell migration, and neuromodulation. How sst2 exerts these
cell type and context specific effects is an important outstanding question.
Additionally, the mechanisms governing neuroendocrine tumor resistance to
somatostatin analogs have yet to be elucidated. Resistance to somatostatin analogs
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is a significant clinical challenge as there are limited additional options to control the
pathological hormone secretion associated with functional NETs. The different
patterns of resistance in pituitary versus GI and pancreatic NETs points to multiple
mechanisms of resistance to somatostatin analogs despite the continued presence
of sst2 on the cell surface of these tumors.
Sst2 has a highly conserved PDZ ligand at its C-terminal tail and what role
this motif plays in sst2 signaling, trafficking, and regulation was unknown before this
study. We hypothesize that uncoupling from sst2’s downstream signaling machinery
is a major mechanism of NET resistance to somatostatin analogs. While many of the
major pathways through which sst2 exerts its effects have been well described,
much is left to learn about sst2’s trafficking, regulation, and cell specific effects. As
PDZ ligand-domain interactions allow for specific spatial and temporal signaling and
regulation of receptors, we asked what effect PDZ protein binding played for sst2
signaling, trafficking, and regulation. We determined that the PDZ ligand plays a
significant role in sst2 intracellular trafficking by showing that the sst2 PDZ ligand
was sufficient for receptor recycling and that sst2 mutants lacking the PDZ ligand or
C-terminal amino acids are routed through different intracellular pathways in
comparison to wild type receptor. We have yet to associate this with an alteration in
signaling. How intracellular trafficking influences receptor signaling is an important
general question to understand how receptors create highly specific signals. We also
determined that sst2 regulation and cell surface expression is influenced by PDZ
domain containing proteins, SHANK3 co-expression increases sst2 plasma
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membrane expression. It is still unclear as to what the mechanism behind this
finding is.
Understanding how SAs exert their effects on NETs is crucial in order to
overcome resistance to SAs and to improve treatments for both hormone secretion
and tumor growth. We have demonstrated that NETs can lose sst2 PDZ binding
partners altering their intracellular trafficking and possibly alters the response to
SAs. The newest clinically used SA, pasireotide, does not cause receptor
internalization, likely altering the signaling profile of sst2 once stimulated in
comparison to SAs such as octreotide. Understanding how PDZ proteins interact
with and affect sst2 will help us better understand how sst2 exerts its effects in a cell
type specific manner and the effects of SA on NET growth and hormone secretion.
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Chapter 2
Methods

2.1 Reagents
Anti-FLAG epitope rabbit polyclonal (600-401-383; 1:5000 for western blot
and 1:2000 for immunocytochemistry) and anti-HA epitope rabbit polyclonal (600401-384; 1:2000 for immunocytochemistry) were purchased from Rockland
Immunochemicals. Anti-HA epitope mouse monoclonal (MMS-101R; 1:10,000 for
western blot, 1:2000 for immunocytochemistry) was purchased from Biolegend. AntiM6PR (cation independent) mouse monoclonal (ab2733; 1:500 for
immunocytochemistry) antibody was purchased from Abcam. Rabbit anti-EEA1 was
purchased from Thermo Fisher (1:2000 for western blot) and mouse anti-LAMP was
purchased from Developmental Studies Hybridoma Bank (H4A3; 1:2000 for western
blot). Mouse anti-SHANK1 (N22/21, Tissue supernatant; 1:2 for western blot),
mouse anti-SHANK2 (N23B/6; 1:1000 for western blot), and mouse anti-SHANK3
(N367/62: 1:1000 for western blot) were purchased from Neuromab (Davis, CA).
Rabbit anti-SHANK3 (H-160; 1:5000 for western blot) and mouse anti-GAPDH
(1:500 for western blot) were purchased from Santa Cruz. Rabbit anti-total ERK1/2
(4695; 1:5000 for western blot) and rabbit anti-p42/44 ERK1/2 (8544; 1:1000 for
western blot) were purchased from Cell Signaling (Danvers, MA). Rabbit anti-GFP
(1:5000 for western blot) was purchased from Thermo Fisher. AlexaFluor fluorescent
secondary antibodies were purchased from Invitrogen. Tat peptides, TAT-AAA:
GRKKRRQRRRPPQGGGLLNGDLQAAA and TAT-SST2:
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GRKKRRQRRRPPQGGGLLNGDLQTSI, to block PDZ interactions were
synthesized by Lifetein (Somerset, NJ). Somatostatin 14 (SS14) and PRL2915 were
purchased from Bachem. [D-Ala2, D-Leu5] Enkephalin (DADLE) and [D-Ala2, NMePhe4, Gly-ol5]-enkephalin (DAMGO) were purchased from Tocris. Naloxone was
purchased from MP Biomedicals. Jetprime transfection reagent was purchased from
Polyplus Transfection (Illkirch, France). Genetecin (G418) was purchased from
Cellgro (Oneonta, NY). Fluo8-AM was purchased from TEFLabs (Austin, TX). FLIPR
membrane potential assay blue component dye was purchased from Molecular
Devices (Sunnyvale, CA).

2.2 Cell Culture, Stable Cell Lines, and Transfections
All cells were grown at 37°C in a humidified 5% C02 incubator. Human
embryonic kidney 293 cells (HEK293) were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Lonza) with 10% fetal bovine serum (FBS)(Atlanta Biologicals).
GH12C1 cells were grown in DMEM with 10% FBS. GH4C1 cells were grown in
Ham’s F12 (F12) media (Lonza) with 12.5% horse serum (HS) (Atlanta Biologicals)
and 2.5% FBS. AtT20 cells were grown in DMEM with 10% FBS. IMR32 cells were
grown in RPMI 1640 media supplemented with 10%FBS and 1% L-glutamine.
CNDT2.5 cells were grown in DMEM/F12 with 10% FBS, 1mM sodium pyruvate,
MEM non-essential amino acids, MEM vitamin solution, and 2mM L-glutamine. BON
cells were cultured in DMEM/F12 +10%FBS. Clonal cell lines stably expressing
receptor plasmid were isolated by limited dilution and cultured in the media of the
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parental cell line supplemented with 250µg/mL Geneticin (G418). Transient
transfections were performed the day before experiments using Jetprime.

2.3 cDNA Constructs
The triple HA-epitope tagged rat sst2 wild type plasmid has been described
previously(82). Triple HA-epitope tagged sst2 ΔTSI (lacking the 3 C-terminal amino
acids, TSI) and sst2 358T (ending at amino acid 358) were made by PCR
amplification using Kapa Hifi polymerase (Kapa Biosystems, Wilmington, MA). Sst2
was amplified from an internal BamHI site to the 3’ end using a mutagenic primer
with a stop codon before the last 3 or 10 amino acids. The PCR product was
digested with BamHI (New England Biolabs) and HindIII (New England Biolabs) and
ligated into sst2. Triple HA-epitope tagged and FLAG-epitope tagged mouse delta
opioid receptor (δOR) constructs were made by amplifying δOR from a cDNA
construct donated by Michael Zhu and digested into pcDNA3.1 with either an Nterminal triple HA tag or a N-terminal FLAG tag with a signal sequence using EcoRI
(New England Biolabs) and XhoI (New England Biolabs). A KpnI cut site at amino
acid 367 of δOR was introduced by PCR into 3xHA-δOR to create the chimeric
receptors. Complementary oligonucleotides spanning the last 30 base pairs of sst2
or spanning the region encoding 7 of the last 10 amino acids of sst2 (lacking the 3
C-terminal amino acids) were purchased (Sigma) and annealed by one cycle of
heating and slow cooling. Both double stranded inserts contained a 5’ KpnI
overhang and a 3’ XhoI overhang to enable ligation into the δOR construct at the
KpnI (New England Biolabs) site. GFP-Rab4 S22N and GFP-Rab11 S25N were
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produced using site directed mutagenesis from GFP-Rab4 and GFP-Rab11
plasmids (Kapa Hifi, Kapa Biosystems, Wilmington, MA). FLAG tagged SHANK PDZ
domain plasmids were made by amplifying the PDZ domains of the three SHANK
proteins from HA-SHANK1 and HA-SHANK3 donated by Carlo Sala and SHANK2
cDNA purchased from the Harvard Plasmid Repository. NotI and BamHI sites were
added by PCR and products were digested and ligated into pFLAG-CMV-6b. GFPSHANK1 (terminates at amino acid 1509 and lacks the SAM domain due to poor
expression of full length clone) was made by amplifying SHANK1 from HA-SHANK1
to add a 5’ HindIII and 3’ SalI site, was ligated into eGFP-C1 (Clontech). GFPSHANK3 was made by PCR from HA-SHANK3, a 5’ EcoRI and 3’ SalI site were
added, and the PCR product was ligated into eGFP-C3. GFP-SHANK2 was made by
PCR from SHANK2 cDNA, a 5’ SalI and 3’ KpnI cut site were added, and the
product was ligated into eGFP-C1. The SHANK3 truncation plasmid GFP-SHANK3
1334T was made by digesting GFP-SHANK3 with EcoRI and KpnI (an internal cut
site) and ligating the truncated product into GFP-C3. GFP-SHANK3 1448T was
made by amplifying SHANK3 from amino acid 1334 to 1448 by PCR and ligating the
product into GFP-SHANK3 1334T using KpnI and XhoI. All plasmids were verified by
sequencing.

2.4 Receptor ELISAs
Cell surface receptors were measured using a colorimetric peroxidase assay
as described previously(80). HEK293 cells were plated in poly-l-ornithine (Sigma
Aldrich) coated 96 well plates 1 day prior to transfection and used for experiments 1
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day after transfection. The day of the experiment, cells were washed with DMEM
with 5 mg/mL Lactalbumin Hydrolysate (LH) and 20 mM HEPES (pH 7.4) and
incubated with primary antibody (mouse anti-HA, 1:10,000, Biolegend) for 2 h at
4°C. After washing twice with DMEM/LH/HEPES and incubating (37°C for 20 min.),
agonist was added (100 nM SS14 or 1 µM DADLE) for the indicate time periods.
Cells were subsequently washed with cold phosphate buffered saline (PBS) and
fixed in 3% paraformaldehyde (PFA) in PBS. To visualize the recycled receptor, cells
were incubated with goat anti-mouse horse radish peroxidase (HRP) in 1% bovine
serum albumin (BSA) in PBS for 1 h at room temperature (RT) and then incubated
with the colorimetric peroxidase substrate, 2,2’-azino-bis(3- ethylbenzthiazoline-6sulfonic acid (ABTS) for 45 min. Absorbance was read at 405 nm. The absorbance
of untransfected wells was subtracted as background and absorbance was
compared to untreated wells on the same plate. To determine total receptor levels,
cells were fixed in 3% PFA, permeabilized with 0.3% Triton X-100 in 1% BSA in PBS
for 20 min at RT, then incubated with anti-HA antibody diluted in the
permeabilization buffer for 1 h at RT, and the rest of the assay was completed in the
same manner as the cell surface ELISA.
To measure sst2 recycling, after cells were incubated with primary antibody
(as described for cell surface experiments), they were then washed twice and
incubated in DMEM/LH/HEPES supplemented with 15 mM NaHCO3 (37 °C in a 5%
CO2 incubator for 20 min). Appropriate agonist, SS14 or DADLE (see figure
legends), was added for 30 min to reach a steady state of internalization (80). Cells
were washed twice with assay media and then incubated with fresh media
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containing either 100 nM PRL2915, an sst2 specific antagonist, or 1 µM Naloxone,
an opioid receptor antagonist, to inhibit the action of residual agonist that remained
in the reaction. The cells were incubated (37°C in 5% CO2) for the time points
indicated and subsequently fixed. They were then incubated with secondary
antibody, followed by color development with ABTS. Recycling assays with GFPRab4 S22N or GFP-Rab11 S25N were performed using the same approach
following transfection with receptor and a vector containing GFP-Rab4 S22N, GFPRab11 S25N, or GFP. Recycling end points were plotted as the extent of recycling
using the formula (%recycled - %internalized)/100 - %internalized.

2.5 Whole Cell cAMP Measurements
Whole cell cAMP was measured using the Glosensor cAMP assay according
to the manufacturer instructions (Promega, Madison, WI). Briefly, HEK293 cells were
transiently transfected with both receptor and Glosensor 22F plasmids. Empty
pcDNA3.1 vector was transfected as a control. The following day, cells were
preincubated in DMEM with 10% FBS and 2% D-luciferin for 2 h at 28°C. Baseline
luminescence readings were taken before the addition of agonist. Cells were
stimulated with either 10 µM NKH477 alone or 10 µM NKH477 plus varying
concentrations of SS14. Luminescence was normalized to NKH477 alone.
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2.6 Immunofluorescence Staining and Confocal Imaging
HEK293 cells were seeded on poly-l-lysine (Sigma Aldrich) coated glass
coverslips. For co-localization with Rab4 or Rab11, cells were transiently transfected
with receptor and either GFP-Rab4 or GFP-Rab11 the day before the experiment.
Cells were incubated at 4°C with anti-HA antibody for 2 h to label receptors. Cells
were subsequently washed in DMEM/LH/HEPES, warmed to 37°C and treated with
100 nM SS14 for 30 min, washed, and incubated with 100 nM PRL2915 for 15 min
to allow for receptor recycling, and then fixed in 3% PFA in PBS. For dual staining of
3xHA-sst2 and FLAG-δOR, cells were preincubated with both mouse anti-HA and
rabbit anti-FLAG antibodies for 2 h at 4°C, washed, warmed in fresh media to 37°C,
treated with both 100 nM SS14 and 1 µM DADLE, and fixed in 3% PFA in PBS.
Cells were blocked and permeabilized using 0.3% Triton X-100 in 10% goat serum
in PBS for 30 min, and incubated with Alexa Fluor conjugated secondary antibodies,
anti-mouse Alexa 568 and anti-rabbit Alexa 488 (Invitrogen), diluted in 10% goat
serum in PBS for 1 h at RT. Cells were washed, co-stained with 1 µg/mL 4’,6diamidino-2-phenylindole (DAPI), and mounted on glass slides using Prolong Gold
Antifade Mountant (ThermoFisher). M6PR staining was performed in a similar
manner except that cells were fixed and permeabilized in cold methanol after
treatment, followed by a 1h incubation with anti-M6PR antibody diluted in 3% BSA in
PBS. Cells were imaged using a Leica SP8 confocal microscope at 63x
magnification and analyzed using ImageJ. Pearson’s correlation coefficients were
generated using ImageJ by comparing images from green and red channels.
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2.7 Immunoprecipitation, Biotinylated Peptide Pulldown, and Western Blots
HEK293 cells were transfected with HA tagged receptors and treated for 15
min with 100 nM SS14 at 37°C for 15 min. Cells were then placed on ice, washed
with cold PBS, and scraped into anti-phosphatase buffer (150 mM NaCl, 20 mM
HEPES, 5 mM EDTA, 3 mM EGTA, 10 mM Na Pyrophosphate, and 10 mM NaF at
pH 7.4). Cell pellets were solubilized using anti-phosphatase buffer with 2 mg/mL
dodecyl β-maltoside, 10 ng/mL leupeptin, 20 ng/mL soybean trypsin inhibitor, 50
ng/mL bacitracin, 1 mM phenylmethylsulfonyl fluoride, and 1 µM okadaic acid for 2 h
at 4°C, and centrifuged (16,000 x g, 20 min). 0.5 ng/mL anti-HA antibody was added
for 1 h followed by 1 h with Protein-G Sepharose. Pellets were washed 3 times with
lysis buffer, eluted in urea sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20%
glycerol, 6M urea), and resolved by 10% SDS-PAGE. After transfer to polyvinylidene
difluoride (PVDF) membrane, immunoprecipitates were tested by western blotting
with previously described sst2 phospho-antibodies(79).
For the biotinylated peptide pulldowns with SHANK PDZ domains, FLAG
tagged SHANK PDZ domains were transiently transfected into HEK293 cells using
Jetprime transfection reagent (Polyplus). Cells were harvested, pelleted, and lysed
in anti-phosphatase buffer with 0.5% Nonidet P40, 10ng/mL leupeptin, 20ng/mL
soybean trypsin inhibitor, 50ng/mL bacitracin, 1mM phenylmethylsulfonyl fluoride,
and 1µM okadaic acid and spun to remove any insoluble material. 4nM of
biotinylated peptides (sst2 or sst2-AAA) were incubated with 50uL streptavidin
agarose beads (Pierce) for 1 hr at 4°C and then washed 3 times with PBS to remove
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any unbound peptide. The remaining free avidin sites were blocked with 10ug of
biotin for 10 min at room temperature. The pellet was then washed again with PBS
to remove unbound biotin. Lysates were pre-cleared with 50uL control agarose
beads for 1 hr at 4°C and centrifuged to remove the agarose. The pre-cleared
lysates were then added to the peptide-streptavidin beads and incubated at 4°C for
2 hrs. Beads were then washed 4 times with 1mL wash buffer (50mM HEPES
pH7.4, 200mM NaCl, 0.5% Triton X100, 0.2% deoxycholate, 1mM PMSF, 10ng/mL
leupeptin, 20ng/mL soybean trypsin inhibitor, and 50ng/mL bacitracin) followed by 1
wash with 100mM Tris pH 8 to remove excess detergents and salt. Bound proteins
were then eluted in SDS buffer for 10 min at 60°C. Eluates were then analyzed by
western blot.
To determine ERK phosphorylation, HEK293 cells stably expressing sst2
were incubated in DMEM/LH/HEPES at 37°C for 20min with 100nM TAT-sst2 or
TAT-AAA peptides. Cells were then treated with 100nM SS14 for the times
indicated, placed on ice, and scraped into HEPES buffer (150mM NaCl, 20mM
HEPES, 5mM EDTA, 3mM EGTA) with 1% Triton X-100. Cells were incubated for
20min on ice and then spun at X g for 20min. Samples were diluted in 2x Laemmli
buffer (1M Tris, 20% glycerol, 10% SDS) and run on 12% SDS-PAGE gel,
transferred to PVDF membranes, blocked with 5% BSA and probed for phosphoERK and then total ERK.
For SHANK immunoblotting, brain cortex and pituitary were dissected from
sacrificed male Sprague Daley rats and mouse cortex was dissected from male
C57/B6 mice and snap frozen with liquid nitrogen. Tissues were then ground,
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homogenized in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS,140 mM NaCl, 1 mM PMSF), left on ice for
15 min and spun to remove insoluble material. Samples were diluted in 2x Laemmli
buffer (1M Tris, 20% glycerol, 10% SDS) and run on 8% SDS-PAGE gel, transferred
to PVDF membranes, blocked with 5% milk and probed using various SHANK
antibodies. Cell lysates were also made using RIPA buffer and mechanically lysed
using a 25 gauge needle.

2.8 Gradient Endosome Separation
HEK293 cells were plated in 10 cm dishes 2 days before the experiment and
transfected with 3xHA-sst2 using Jetprime the day before the experiment. Cells were
washed twice and incubated at 37°C for 20 min prior to the addition of agonist. 100
nM SS14 was added for the indicated times. Cells were washed with cold PBS,
scraped into cold PBS, and pelleted by centrifugation (3000 x g, 10 min). Postnuclear supernatants were isolated and loaded on top of a continuous Opti-prep
gradient (Sigma, 10-20%) and centrifuged (150,000 x g, 12 h, 4°C) in a swinging
bucket rotor (TLS-55, Beckman). Fractions (150 µL) were collected and diluted in
homogenization (HB) buffer (20 mM HEPES pH 7.4, 0.25 M sucrose, 2 mM EGTA, 2
mM EDTA, 0.1 mM DTT and a protease inhibitor cocktail (112 µM PMSF, 3 µM
aprotinin, 112 µM leupeptin, 17 µM pepstatin) (150 µL) followed by centrifugation
(150,000 x g, 1 h, 4°C). The resulting pellet was resuspended in urea sample buffer
for western blotting or diluted in HB for use in the endosomal budding assays (see
below).
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2.9 Cytosol Preparation
The Saccharomyces cerevisiae strains, wild type (MATa; his3Δ 1; leu2Δ 0;
met15Δ 0; ura3Δ 0) and ΔSNX1/2 (MATa; his3Δ 1; leu2Δ 0; ura3Δ 0; met15Δ 0;
snx1::KANMX6) were plated on yeast extract peptone dextrose (YPD plates) (500
mL ddH20 containing: 10 g bactopeptone, 5 g yeast extract, 8 g agar, 25 mL 40%
dextrose) and incubated for 48 h in a shaker at 30°C. YPD media (5 mL) was
inoculated with various Saccharomyces cerevisiae strains and incubated overnight
in a shaker at 30°C. Cultures were transferred into a secondary culture of YPD
media (50 mL) and were grown until OD600 reached 0.8-1.0. For Saccharomyces
cerevisiae ΔSNX1/2, the strain was grown in YPD media containing G418 (500
µg/mL). Cells were collected by centrifugation (3000 x g, 3 min) and washed twice,
first with 500 µL of ddH2O followed by 500 µL Tris protease TP buffer (20 mM Tris,
pH 7.9; 0.5 mM EDTA; 10% glycerol; 50 mM NaCl, 112 µM leupeptin, 3 µM
aproptinin, 112 µM PMSF, and 17 µM pepstatin). Cells were collected by
centrifugation (3000 x g, 3 min), resuspended in TP buffer (130 µL), and lysed using
acid-washed glass beads (1 min vortex; 1 min incubation on ice, 5x) prior to
centrifugation (3000 x g, 10 min) for supernatant collection. Protein concentration in
the supernatants was measured by Bradford assay. Supernatants were divided into
70 µg aliquots and stored at -80 °C.

2.10 Endosomal Budding Assays
For endosomal budding assays, cells were lysed and endosomes were
separated on Opti-prep gradients. Gradient fractions containing late endosomes
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were pooled and incorporated into the cell-free budding assay. Late endosome
fractions were diluted in HB (400 µL) and centrifuged (150,000 x g, 1 h, 4°C). The
resulting pellets were resuspended in 15 µL HB and membranes were used in cellfree reactions as described(146). Endosomal membranes were either incubated on
ice (starting material) or incorporated into reactions containing yeast cytosol. A
standard reaction (50 µL) contained 15 µL endosomal membranes, 6 µL ATP
regeneration system (2 mM Mg-ATP, 50 µg/mL creatine kinase, 8 mM
phosphocreatine, 1 mM DTT), 70 µg of Saccharomyces cerevisiae cytosol, and HB
in a total reaction volume of 50 µL. Experimental reactions were incubated for 3 h at
37°C, followed by trypsin-treatment (6 µl of 0.27 µg/µL trypsin; 30 min, 4°C).
Reactions were centrifuged (20,000 x g, 30 min, 4°C), supernatants were collected
and further centrifuged (150,000 x g, 1 h, 4°C) to obtain outwardly budded vesicles.
After ultracentrifugation, the resulting pellet was resuspended in Laemmli sample
buffer for SDS-PAGE. Control reactions (starting material) remained on ice
throughout the entirety of the experiment and were resuspended in Laemmli sample
buffer for SDS-PAGE. Proteins were then transferred to PVDF membrane and
assessed by western blotting using the denoted antibodies and visualized using
enhanced chemiluminescence. The resulting band densities were quantified using
ImageJ.

2.11 Membrane Hyperpolarization Assays
GH12C1 cells were plated in black walled 96 well plates 1 day prior to the
experiment. Cells were washed once with assay buffer (140mM NaCl, 2mM CaCl,

	
  

37	
  

1mM MgCl, 5mM KCl, 10mM Glucose and 10mM HEPES, pH 7.4) and cells were
then incubated with FLIPR Membrane Potential Assay Blue Component dye
(Molecular Devices) in assay buffer and 100nM TAT-AAA or TAT-sst2 and incubated
at 37°C for 30 min in the Flexstation 3 (Molecular Devices). Cells were excited at
530nM and measured fluorescence was read at 565nM for 30 sec before the
addition of 100nM SS14 diluted in assay buffer and for 5 min after the addition of
agonist. Fluorescence was normalized to readings before the addition of agonist.

2.12 Intracellular Calcium Measurements
GH12C1 cells were plated in black walled 96 well plates 1 day prior to the
experiment. The day of the experiment, cells were washed with ECSP buffer
(140mM NaCl, 2mM CaCl, 1mM MgCl, 5mM KCl, 10mM Glucose and 10mM
HEPES, pH 7.4), and 50µl of ECSP buffer with 1mM Fluo-8 AM (TEFLabs), 0.01%
bovine serum albumin (BSA), and 2mM probenecid were added to each well and
cells were incubated at 37°C for 45 min with 100nM TAT-AAA or TAT-SST2. Cells
were then washed and fresh ECSP buffer was added. Cells were then incubated at
37°C in the Flexstation 3 (Molecular Devices) for 15 min. Cells were excited at 494
nM and measured fluorescence was read at 535 nM for 30 sec before the addition of
100nM SS14 diluted in assay buffer and for 5 min after the addition of agonist.
Fluorescence was normalized to readings before the addition of agonist.
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2.13 Polymerase Chain Reaction
Brain cortex and pituitary were dissected from sacrificed male Sprague Daley rats
and mouse cortex was dissected from male C57/B6 mice and snap frozen with liquid
nitrogen. RNA was made using the GeneJET RNA purification kit (ThermoFisher)
according to protocol and subsequently treated with DNase (New England Biolabs).
cDNA was made using the Transcriptor First Strand cDNA Synthesis Kit (Roche)
along with appropriate no reverse transcriptase controls. PCR products were
amplified using GoTaq (Promega). Conditions were as follows: 35 cycles of 95°C for
30s, 58°C for 30s, 68°C for 20s. Products were resolved on a 2% agarose gel
stained with SybrSafe (Invitrogen). Primers were purchased from Sigma Aldrich and
are listed below. Human pituitary and pituitary tumors cDNA samples were analyzed
by RT-PCR at Massachusetts General Hospital using the conditions above.
Name
rSHANK1 Fwd
rSHANK1 Rev
rSHANK2 Fwd
rSHANK2 Rev
rSHANK3 Fwd
rSHANK3 Rev
rEef Fwd
rEef Rev
rsst2 Fwd
rsst2 Rev
rsst5 Fwd
rsst5 Rev
mSHANK1 Fwd
mSHANK1 Rev
mSHANK2 Fwd
mSHANK2 Rev
mSHANK3 Fwd
mSHANK3 Rev
msst2 Fwd
msst2 Rev
msst5 Fwd

	
  

Sequence
GTGAGGGGTTCGGGTTCGTG
TCATGTTGACCACCTGGCGG
CGGCATTACACAGTGGGCTCCT
TTCTATGGCCACGTTCTCTGCAGTC
CTGTGGGTTCCTATGACAGC
CGAGCACTATCCTCCTCTGG
ATTGTGGGGTTGGTCGGGGT
CACCTCCTCGGTGGATGGCA
AAGATGTCACGATAGACCCTTG
CACGGACGAGACATTGAAGATA
GTCCTGCACAGAGACACG
GCATTCAAATCCTGCTGGTC
AAGTGCTCAGCATCGGGGAA
TCTTCTTCCAGGGGGAGACCA
CGGCATTACACGGTGGGCTCCT
AGGGTCTAGATTCCTGGTCACCGT
CTGTGGGTTCCTATGACAGC
CGAGCACCATCCTCCTCGGG
GCTGGCTCCCCTTCTACATC
TGTCCTGCTTACTGTCGCTC
GGACTGGGTGGAAACACACT
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msst5 Rev
mEef Fwd
mEef Rev
hSHANK1 Fwd
hSHANK1 Rev
hSHANK2 Fwd
hSHANK2 Rev
hSHANK3 Fwd
hSHANK3 Rev
hsst2 Fwd
hsst2 Rev
hEef Fwd
hEef Rev

GAGACAGCATTCTGCGTTGC
ATTGTGGGGCTGGTCGGAGT
CACCTCCCCGGTGAATGGCA
GTGAGGGGTTTGGGTTCGTG
TCATGTTCACCACCTGTCGG
AGGCACTACACCGTGGGCTCCT
TTCCACAGCCATGTTCTCAGCAGCG
TGATGACAAAGTGGCTGTCCT
CACAACCTTCATGACGAGGC
TGAGCTCTTCATGCTGGGTC
TAGAGGAGCCCACTCGGATT
GACAGCGAGGACAAGGACAA
CGATGATGTGCTCTCCCGAC

Table 1: List of primers. Primers were designed to specifically amplify the PDZ
domains of the three SHANK proteins. All primers were designed using Primer3.

	
  
2.14 Data Analysis
Data analysis was performed using Prism 7 (Graphpad). Analysis of variance
(ANOVA) or other appropriate statistics were performed as indicated based on the
assay and a p value of <0.05 was considered significant.
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Chapter 3
Regulation of Somatostatin Receptor 2 trafficking and signaling by C-terminal
motifs and the retromer

3.1 Introduction
G protein coupled receptors (GPCRs) constitute the largest family of
membrane receptors, which activate a variety of signaling pathways in response to
extracellular stimuli. The majority of GPCRs are internalized after ligand binding,
following which they are either recycled back to the plasma membrane or sorted into
degradation pathways from which they will be degraded in lysosomes or by the
proteasome (71, 92, 95, 147, 148). The intracellular fate of GPCRs is often regulated
by C-terminal structural elements including postsynaptic density protein (PSD95),
Drosophila disc large tumor suppressor (Dlg1), zonula occludens-1 protein (ZO-1)
(PDZ) ligands and other protein-protein binding motifs (70, 86, 87, 93, 149). These
motifs are sufficient to route receptors into specific recycling or degradation
pathways through interactions with cytoplasmic and endosomal sorting proteins (94,
124, 126, 128). Additionally, PDZ proteins play significant roles in modulating
receptor signaling either through directly coupling receptors with downstream
signaling pathways or through altering receptor trafficking. Understanding how
receptors are sorted following internalization is crucial to understanding how a
receptor creates a highly specific signal while acting on common pathways.
The Gi-coupled GPCR, somatostatin receptor 2 (sst2), is a clinically important
GPCR as it is the drug target of somatostatin analogs such as octreotide, lanreotide,
and pasireotide. Treatment with these agonists is the main medical approach for
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controlling excessive hormone secretion from neuroendocrine tumors (1, 2, 12, 16).
Activation of sst2 decreases hormone secretion by inhibiting cAMP production and
decreasing intracellular calcium concentrations (51, 54, 55). In addition, treatment
with somatostatin analogs has been shown to decrease tumor growth (2, 16).
Although some of the signaling and regulatory pathways of sst2 have been studied
in great detail, little is known about its fate after internalization, or of the structural
motifs in its cytoplasmic domain, which determine its intracellular trafficking pathway
(7, 48, 66, 79-83). Sst2 has a highly evolutionarily conserved C-terminal class I PDZ
ligand in its C-terminal tail, which has been shown to bind to several proteins,
including SHANK1, SHANK2, and PDZK1 (88-91). Although PDZ ligands often
regulate GPCR intracellular trafficking, recycling, and signaling, no function has
been ascribed to PDZ protein binding by sst2 (70, 86, 126).
In addition to interaction with PDZ domain proteins, GPCR intracellular
trafficking is often regulated by Rab proteins, which cycle on and off endocytic
membranes and play regulatory roles in recycling events from various endocytic
pathways (71, 106, 150-152). For example, Rab4 can regulate endosomal trafficking
to the plasma membrane from early endosomes, and Rab11 regulates vesicle
movement to the plasma membrane from a perinuclear recycling compartment (106,
109). Movement of GPCRs through these different populations of Rab containing
endosomes depends on their ability to interact with cytoplasmic proteins and their
post-translational modifications. For example, endocytic recycling of the β2adrenergic receptor (β2AR) is dependent on protein-protein binding through its PDZ
ligand. Similarly, recycling of the µ-opioid receptor (µOR) is dependent on its
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phosphorylation, which determines its itinerary to the plasma membrane through
Rab4 or Rab11 positive endosomes (112, 124).
Aside from direct recycling from Rab 4 or Rab 11 positive compartments, an
additional pathway for plasma membrane recycling routes proteins through the
trans-Golgi Network (TGN) prior to plasma membrane targeting (153). Sst2 has, in
fact, been shown to transit to the TGN in HEK293 cells and primary neurons (82, 85,
154). The retromer complex of coat proteins, which is composed of five polypeptides
(SNX1/2, SNX5/6, Vps26, Vps29, and Vps35), acts to sort cargo from the late
endosome to the TGN during retrograde trafficking (115). Given that the retromer
complex is involved in the trafficking of some GPCRs, including the β2AR and the
parathyroid hormone receptor 1 (PTHR1) (75, 116), and that sst2 is partially
localized in the TGN in both HEK293 cells and neurons, we hypothesized that the
retromer complex plays a role in sorting sst2 at endosomes (85, 154).
In addition to the role in trafficking, PDZ proteins play a significant role in
GPCR signaling. Binding to PDZ proteins allows GPCRs to alter G-protein signaling,
couple to ion channels, and allow receptors to affect downstream signaling pathways
such as the ERK/MAPK pathways amongst others(87). PTHR1 can bind to NHERF2
through its PDZ domain, which alters PTHR1 signaling from primarily being through
adenylyl cyclase to PLC(155). mGLUR5 can couple to potassium channels through
PDZ protein binding, Ret9 requires its PDZ ligand to effectively activate the
ERK/MAPK pathway, and there are numerous addition examples of PDZ protein
interactions allowing receptors and GPCRs to regulate these pathways(156, 157).
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As the main clinical role of sst2 is to decrease hormone secretion from
neuroendocrine tumors, we asked if the PDZ ligand of sst2 played a role in the
pathways known to affect hormone secretion. Sst2 primarily couples to Gi/Go
proteins to inhibit adenylate cyclase (AC)(8, 10, 51). The inhibition of AC and
subsequent reduction of cAMP levels is the main mechanism through which sst2 can
inhibit hormone secretion(52). Additionally, there are other cAMP-independent
mechanisms through which sst2 can inhibit hormone secretion. The activation of
Gi/Go proteins by sst2 in GH4C1 and GH12C1 cells can activate potassium channels
(such as G-protein gated inward rectifier) leading to membrane hyperpolarization.
The subsequent inhibition of voltage dependent calcium channels due to membrane
hyperpolarization causes a decrease in intracellular calcium(51, 54, 55). Reduction
of either cAMP or intracellular Ca2+ will lead to a decrease in hormone secretion,
and together the effect is synergistic (Fig 2) (55). The effect on K+ channels is
pertussis toxin (PTX) sensitive, indicating the necessity of Gi/Go proteins, and
independent of the cAMP levels, as activation of sst2 is able to hyperpolarize the cell
membrane even in the presence of a stable cAMP analog(54, 55). Sst2 has also
been shown to regulate calcium channels directly, through direct inhibition also in a
PTX-dependent manner(55). We asked if any of these mechanisms were dependent
on the sst2 PDZ ligand. Additionally, we determined if the PDZ ligand affected sst2’s
ability to signal to the ERK/MAPK pathway.
We have found that the PDZ ligand plays a significant role in sst2 trafficking.
The last 10 amino acids including the PDZ ligand are sufficient for receptor recycling
and the presence of the PDZ ligand and last 10 amino acids allows for sst2 to
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access different recycling pathways. We also determined that trafficking of sst2 from
the late endosome to the TGN is dependent on the presence of SNX1/2, a
component of the retromer. Overall, the last 10 amino acids and the PDZ ligand play
an important role in sst2 endosomal sorting and trafficking.

3.2 Results
3.2.1 Sst2 C-terminal and PDZ ligand truncation mutants are expressed on the cell
surface and can couple to Gi
Sst2 is a Gi coupled GPCR that is activated by the endogenous ligand, somatostatin
14 (SS14)(3, 51). After activation, the receptor is rapidly phosphorylated by Gprotein receptor kinases (GRKs), binds to β-arrestin, and undergoes clathrindependent endocytosis (80, 83). Given that PDZ ligands and C-terminal motifs
regulate trafficking for other GPCRs, we created two triple HA-tagged truncation
mutants, one lacking the last 3 amino acids of the C-terminus (sst2 ΔTSI) and the
other lacking the last 10 amino acids (sst2 358T) (Fig. 5A). We expressed these
mutant receptors in HEK293 cells and measured their cell surface expression and
their ability to inhibit cAMP production. We observed that the mutant receptors were
expressed at the cell surface, although not to the same extent as the wild type
receptor (Fig. 5C). We then asked if the differences in surface expression were due
to the accumulation of intracellular receptor. Interestingly, sst2 358T exhibited very
little intracellular expression. Sst2 ΔTSI exhibited a trend towards reduced
intracellular expression, although this was not statistically significant (Fig. 5D).
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These data suggest that the 10 C-terminal amino acids may play a role in retaining
sst2 in intracellular compartments. To determine whether these mutant receptors
were able to regulate cAMP production, we used the Promega Glosensor assay to
measure whole cell cyclic AMP (cAMP) concentrations in cells treated with the
forskolin analog NKH477 and SS14. We observed that both sst2 ΔTSI and sst2
358T inhibited NHK477-induced cAMP accumulation in HEK293 cells (Fig. 5B),
indicating that they couple as efficiently to Gi/o as the wild type receptor. The
determination that the two sst2 mutants can reach the cell surface and couple to G
proteins is consistent with the behavior of other GPCR mutants lacking their PDZ
ligands, including LHR and β2AR (72, 124).
Sst2 internalization and desensitization is regulated by multiple
phosphorylation sites in the C-terminal tail that are upstream of the final 10 amino
acids, including a serine cluster at amino acids 341 and 343 (Ser-341/343) and a
threonine cluster at amino acids 353 and 354 (Thr-353/354). The serine cluster is
important for desensitization, and the threonine cluster is required for β-arrestin
recruitment and receptor internalization (79). Importantly, phosphorylation of GPCRs
may be dependent on PDZ interactions. For example, phosphorylation of a third loop
site of the beta-1 adrenergic receptor (β1AR) is dependent on an intact PDZ ligand
and its interaction with SAP97 (128). Thus, we examined whether the sst2 Cterminal truncation mutants could be phosphorylated at Ser-341/343 and/or Thr353/354 using previously validated phosphorylation-specific antibodies for sst2. We
determined that both the serine and threonine clusters in each sst2 mutant were
phosphorylated after treatment with SS14 to a similar extent as the wild type
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receptor (Fig. 6). These data indicate that changes in C-tail phosphorylation are not
responsible for altered behavior of the two sst2 mutants.
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Figure 5: Functionality of sst2 C-terminal mutants. A) Diagram of sst2 showing
mutants lacking the last 3 (ΔTSI) or 10 C-terminal (358T) amino acids. B) HEK293
cells were transfected with the Promega Glosensor 22F cAMP plasmid and sst2
receptors. Cells were stimulated with the forskolin analog NKH477 (10 µM) alone, plus
or minus SS14 (100 nM). Luminescence was normalized to cells stimulated with
NKH477 alone and plotted to determine extent of cAMP inhibition for each receptor.
Data are shown as the mean ± SEM for 3 independent experiments. C) Surface
expression of sst2 ΔTSI and sst2 358T was measured by ELISA and compared to wild
type receptor. Data are the mean ± standard error of the mean (SEM) of 3 independent
experiments. D) Cell surface receptor levels were compared to total receptor by ELISA
for sst2, sst2 ΔTSI and sst2 358T. Data are the average ± SEM of 3 independent
experiments. (n.s. = not significant; * = p<0.05, ** = p<0.005).

	
  

48	
  

Figure 6. C-tail phosphorylation of sst2 mutants. HEK293 cells were transfected
with HA-tagged sst2, sst2 ΔTSI, or sst2 358T and stimulated with SS14 (100 nM)
for 15 min. Lysates were probed with antibodies specific for the phosphorylation
sites shown, and then reprobed for HA-epitope.
	
  

3.2.2 The sst2 PDZ ligand and 10 C-terminal amino acids are not required for overall
internalization and recycling
Using a previously developed cell surface receptor ELISA, we examined the
rate and extent of internalization and recycling of both sst2 ΔTSI and sst2 358T (80).
HEK293 cells were transiently transfected with wild type sst2, sst2 ΔTSI, or sst2
358T and treated for various times with a saturating concentration of SS14 (100 nM)
to determine the extent of internalization. We hypothesized that the rate and extent
of internalization would not be affected since both mutants can be phosphorylated at
the threonine cluster responsible for β-arrestin binding and internalization (Fig. 6).
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We observed that there were no significant differences in the rate or extent of
internalization of sst2 ΔTSI or sst2 358T compared to wild type receptors (Fig. 7A).
PDZ ligands often act as recycling signals for receptors. For example, the β1AR,
β2AR, LHR, and kappa opioid receptors cannot efficiently return to the plasma
membrane after ligand stimulation without binding to PDZ domain containing
proteins (124, 128, 158, 159). We therefore hypothesized that sst2 ΔTSI and sst2
358T would not recycle to the plasma membrane. Surprisingly, both sst2 mutants
were able to recycle to the same extent and at the same rate as the wild type
receptor (Fig. 7B). These data suggest that the PDZ ligand and 10 C-terminal amino
acids of sst2 are not required for overall internalization or recycling.
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Figure 7. Sst2 ΔTSI and sst2 358T internalize and recycle equally to wild type
sst2. A) HEK293 cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T.
The rate and extent of internalization after treatment with SS14 (100 nM) was
measured using cell surface receptor ELISA. Values were normalized to untreated
wells. Data are shown as the average ± SEM for 3 independent experiments. B)
HEK293 cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T. Cells
were treated with SS14 (100 nM) for 30 min to induce maximal internalization of
receptors. Agonist was then removed and fresh media containing 100 nM PRL2915
(an sst2 specific antagonist) was added. Cells were allowed to recover for various
times before fixation and cell surface receptor was normalized to untreated wells. Data
are shown as the mean ± SEM for 3 independent experiments. There was no
significant difference in the rate or extent of internalization or recycling for either mutant
compared to wild type sst2, as determined by sum of squares F test.
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3.2.3 The sst2 ΔTSI and sst2 358T mutants uncover receptor regulation by Rab4
and Rab11
As PDZ ligands can also affect intracellular trafficking without affecting the
ability of a receptor to return to the plasma membrane, we determined if sst2, sst2
ΔTSI, and sst2 358T were trafficked through the same pathways (75). Many
receptors recycle through Rab4- or Rab11-positive compartments (112, 160). Thus,
we contrasted the ability of dominant negative versions of Rab4 or Rab11 to affect
recycling of wild type or mutant sst2 receptors at steady state. We observed that coexpression of dominant negative Rab4 or Rab11 did not affect wild type sst2
internalization or recycling (Fig. 8A, B). The dominant Rab proteins were functional
in this assay, as they inhibited recycling of the µOR (data not shown). On the other
hand, expression of either dominant negative Rab4 or Rab11 inhibited the extent of
sst2 ΔTSI recycling without affecting internalization (Fig. 8C, D). Interestingly, only
expression of the Rab11 dominant negative protein inhibited sst2 358T recycling
(Fig. 8E, F). These results suggest that while sst2 may be able to access numerous
recycling pathways, sst2 ΔTSI recycling may be more limited and is dependent on
the function of both Rab4 and Rab11 proteins. Similarly, sst2 358T is dependent on
Rab11 protein function.
To confirm these observations, we assessed whether wild type and mutant
sst2 receptors colocalized with GFP-Rab4- or GFP-Rab11-positive endosomes
during recycling. We observed that wild type sst2 colocalizes with Rab4 and Rab11
after 15 min of recycling (about the half-time of recycling) (Figs. 10 and 11). These
data indicate that wild type sst2 can access both of these pathways, but is not
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dependent on either for recycling. Surprisingly, sst2 ΔTSI and sst2 358T did not
colocalize to the same extent with Rab4 as wild type sst2, indicating that the Cterminus plays a role in trafficking sst2 into Rab4-positive endosomes (Figs. 10 and
11). We did not find a significant change in colocalization with Rab11 for either
mutant.

Figure 8. Dominant negative versions of Rab4 and Rab11 inhibit recycling of sst2
ΔTSI and sst2 358T, but not wild type sst2. (A, C, E) HEK293 cells were transiently
transfected with GFP-tagged dominant negative mutants of Rab4 or Rab11 plus sst2 (A),
sst2 ΔTSI (C), or sst2 358T (E). An empty GFP vector was used as a control. Cells were
treated for 30 min with SS14 (100 nM). Cell surface receptor was measured by ELISA and
compared to untreated controls. Data are shown as the mean ± SEM for 3 independent
experiments. (B, D, F) Recycling of sst2 (B), sst2 ΔTSI (D), or sst2 358T (F) with Rab
dominant negatives. Cells were transfected as in (A) and treated for 30 min with SS14
(100 nM). Cells were then washed, fresh media with 100 nM PRL2915 was added, and
the cells were incubated for 30 min. Cell surface receptor was measured by ELISA and
compared to untreated controls. Data are shown as the mean ± SEM for 3 independent
experiments (n.s. = not significant; * = p<0.05, ** = p<0.005).
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Figure 9. Colocalization of sst2, sst2 ΔTSI, and sst2 358T with Rab4. A) HEK293 cells
were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T and GFP-Rab4. Cells were
treated for 30 min with SS14 (100 nM), washed, fresh media with PRL2915 (100 nM) was
added, and the cells were incubated for 15 min before being fixed and stained for
immunofluorescence. Scale bars are 10 µm. B) Co-localization of sst2 and Rab4 during
recycling. Data are the mean ± SEM for 3 independent experiments, with at least 6 cells
quantified per experiment (**** = p<0.0001).
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Figure 10. Colocalization of sst2, sst2 ΔTSI, and sst2 358T with Rab11. A) HEK293
cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T, and GFP-Rab11.
Cells were treated for 30 min with SS14 (100 nM), washed, fresh media with PRL2915
(100 nM) was added, and incubated for 15 min before being fixed and stained for
immunofluorescence. Scale bars are 10 ìm. B) Co-localization of sst2 receptors and
Rab11 during recycling. Data are the mean ± SEM from 3 independent experiments, with
at least 6 cells quantified per experiment. (n.s. = not significant).
	
  

	
  

56	
  

3.2.4 Sst2 traffics from early to late endosomes during endocytosis
Sst2 is internalized from the plasma membrane into clathrin-coated pits and
traffics into early endosomes shortly after stimulation with ligand. However later
trafficking events of sst2 have not been well described (79, 81, 83). Given that sst2
recycling is not inhibited by dominant negative Rab11, we hypothesized that sst2
was trafficking to late endosomes before being recycled to the plasma membrane.
To assess whether this was the case, we determined the localization of wild type
sst2 following SS14 stimulation using velocity gradient separation of endosomal
organelles. We observed that sst2 is mostly colocalized with the early endosomal
marker EEA1 after 2 min of agonist stimulation and is localized in both early and late
endosomal fractions after 5 min stimulation. Thirty minutes after stimulation sst2
moves into the late endosomal compartment (Fig. 11). Because our recycling assays
begin after 30 min of SS14 stimulation, these data suggest that sst2 can recycle
from late endosomal compartments.
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Figure 11. Sst2 internalizes through early endosomes and traffics to late
endosomes. HEK293 cells were transfected with HA-sst2 and treated for 2, 5, or
30 min with SS14 (100 nM) to induce receptor internalization. Cells were lysed
and endosome fractions were separated by centrifugation. Fractions were
collected and analyzed by western blot. EEA1 is a marker for early endosomes
and LAMP1 is a marker of late endosomes.	
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3.2.5 The 10 C-terminal amino acids of sst2 are sufficient to dictate receptor
recycling from late endosomes
The delta opioid receptor (δOR) is a Gi-coupled GPCR that traffics from early to late
endosomes after stimulation with ligand. However, after trafficking to late
endosomes, δOR is degraded in lysosomes instead of recycling to the plasma
membrane (70). The fate of δOR after endocytosis can be altered by adding
recycling sequences to the C-terminal tail to create a chimeric receptor (126, 127).
For example, replacing the 6 C-terminal amino acids of δOR with the 10 C-terminal
amino acids of the β2AR or other class I PDZ ligands such as β1AR or the cystic
fibrosis transmembrane receptor, alters the fate of receptor from lysosomal
degradation to plasma membrane recycling. Importantly, removing the 6 C-terminal
amino acids of δOR does not change its trafficking or degradation (127). To
determine if the 10 C-terminal amino acids of sst2 can act as a recycling sequence,
we created two δOR chimeras in which the last 6 amino acids of δOR were replaced
with the 10 C-terminal amino acids of sst2 or 7 of the last 10 without the PDZ ligand
(Fig. 12A). We determined that these chimeras are expressed at the cell surface
similarly to δOR (data not shown) and can couple equivalently to Gi to inhibit cAMP
(Fig. 12B). We then determined whether the C-terminal sst2 tail was sufficient to
alter internalization or recycling. We observed that δOR, δOR sst2, and δOR sst2
ΔTSI internalized to similar extents after 30 min of treatment with 1 µM DADLE, a
specific δOR agonist (Fig 12C). For the recycling assays, cells were treated for 30
min with 1 µM DADLE, washed, and 1 µM naloxone was added to block any residual
agonist action. We observed that the δOR-sst2 and δOR sst2 ΔTSI chimeras
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recycled to the plasma membrane more efficiently than δOR (Fig. 12D). These data
suggest that additional determinants within 7 amino acids adjacent to the PDZ ligand
are involved in regulating sst2 recycling. We also examined the intracellular
localization of sst2 as compared to δOR in the same cells after treatment with both
SS14 and DADLE for 30 min. Interestingly, δOR was almost completely localized in
cytoplasmic puncta whereas sst2 was localized in both cytoplasmic puncta and a
perinuclear compartment (Fig. 12E). This perinuclear compartment may be the TGN,
as sst2 is found in the TGN in ligand stimulated HEK293 cells and primary neuronal
cultures (82, 85, 154). These data indicate that the C-terminus of sst2 acts as a
sorting signal, most likely at the late endosome, and is sufficient to direct recycling of
a heterologous receptor.

Figure 12. The 10 C-terminal amino acids of sst2 are sufficient for receptor
recycling from late endosomes. A) Diagram depicting amino acid changes for the
δOR chimeras. B) Effects of δOR, δOR sst2, or δOR sst2 ΔTSI stimulation on cAMP
levels as measured using the Promega Glosensor cAMP assay. HEK293 cells were
transiently transfected with receptor (or empty vector as a control) and the Glosensor
22F plasmid. Cells were stimulated with the forskolin analog NKH477 (10 µM) alone or
plus the δOR agonist DADLE (1 µM). Data are normalized to NKH477 treatment alone
and plotted as the mean ± SEM from 3 independent experiments. C) Internalization of
the δOR chimeras was measured using cell surface ELISA. D) Recycling of δOR
chimeras. HEK293 cells were transiently transfected with the receptors shown, treated
for 30 min with 1 µM DADLE, washed, and incubated in fresh media with the δOR
antagonist naloxone (1 µM) for 30 min. Data are plotted as the extent of recycling. E)
HEK293 cells were transiently transfected with HA-sst2 and FLAG-δOR and treated for
30 min with both SS14 (100 nM) and DADLE (1 µM) to induce internalization. Cells
were fixed and stained for immunofluorescence. The Pearson’s correlation coefficient
for colocalization sst2 and δOR receptors was 0.69± 0.02 (mean ± SEM) for at least 6
cells per experiment from 3 independent experiments. Scale bar is 10 ìm. (n.s. = not
significant, **:p<0.005, ****: p<0.0001).
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3.2.6 The C-terminal tail of sst2 targets it to the trans-golgi network
As our results indicate that sst2 recycles from the late endosome and that the 10 Cterminal amino acids are sufficient for recycling, we hypothesized that the 10 Cterminal amino acids of sst2 direct trafficking from late endosomes to the TGN to
allow recycling to the plasma membrane. Sst2 has previously been shown to
colocalize with the cation-independent mannose-6-phosphate receptor (CI-M6PR), a
TGN marker, after treatment with 100 nM SS14 in HEK293 cells(82). Thus, we used
confocal microscopy to assess whether sst2 ΔTSI or sst2 358T co-localized with CIM6PR after 30 min of treatment with 100 nM SS14. We observed that significantly
less sst2 358T colocalized with the CI-M6PR (Fig 13A, B), suggesting that the 10 Cterminal amino acids direct sst2 to the TGN.

3.2.7 Sst2 budding from late endosomes is dependent on retromer components
Late endosome to TGN trafficking is usually dependent on retromer components
(115). To determine whether sst2 budding from the late endosome is retromerdependent, we used a cell-free assay that measures the budding of vesicles from
late endosomal membranes and is dependent on cytosolic factors (146, 151). In this
assay endosomes are separated by density gradient centrifugation, and late
endosomes can then be incubated with ATP and either complete yeast cytosol or
yeast cytosol lacking individual trafficking proteins (Fig. 13C). Thus, this assay takes
advantage of the homology between yeast and human trafficking proteins to allow
one to unequivocally identify proteins are that required for endosomal budding. Cells
transfected with sst2 were stimulated with SS14 30 min, lysed, and endosomal
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membranes were isolated. We then examined whether sst2 was capable of budding
from late endosomal membranes. We also determined whether cytosol lacking
SNX1/2, which is a component of the retromer complex, affected sst2 budding. We
observed that wild type cytosol supported significant budding of sst2 from the late
endosomal fraction, but that significantly less budding of sst2 occurred when using
the cytosol lacking SNX1/2 was used (Fig 13D). The dependence of sst2 budding on
retromer components is consistent with the observation that sst2 traffics to the TGN.
Overall, our data indicate that sst2 is internalized into early endosomes, traffics to
late endosomes, and buds from the late endosome in a retromer-dependent fashion,
presumably to allow movement to the TGN and ultimately recycling to the plasma
membrane. Moreover, the 10 C-terminal amino acids of sst2 appear to be sufficient
for recycling from late endosomes and help direct the receptor to the TGN.
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Figure 13. Sst2 trafficking from the late endosome to the trans-golgi network is
dependent on the last 10 C-terminal amino acids and the retromer complex. A)
HEK293 cells were transiently transfected with HA-tagged sst2, sst2 ΔTSI, or sst2
358T, treated with SS14 (100 nM) for 30 min, and fixed. Cells were co-stained for
HA-epitope (green) and M6PR (red) to mark the trans-golgi network. Scale bars are
10 ìm. B) Colocalization of M6PR and sst2 mutants. Data are the mean ± SEM for 6
cells per experiment from 3 independent experiments. Pearson’s correlation
coefficient (PCC) for the two sst2 mutants was compared to sst2 (p = 0.12 for sst2
ÄTSI; p = 0.0045 for sst2 358T). C) Diagram of in vitro endosome sorting assay.
Cells expressing HA-sst2 were treated with SS14 (100 nM) for 30 min to allow
receptors to internalize and reach late endosomes. Cells were then mechanically
lysed and the endosomal fractions were separated by centrifugation through a
continuous gradient. The late endosome fractions were collected and incubated with
either complete or ΔSNX1/2 yeast cytosol for 3 hours at 37°C to allow for receptor
budding from the endosomes. The mixture was then centrifuged to pellet the heavier
multivesicular bodies and the supernatant was collected, pelleted, dissolved in
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sample buffer, and resolved by SDS- PAGE to determine the extent of receptor
budding. D) Quantification and representative western blots of sst2 budding after
incubation with complete or ΔSNX1/2 yeast cytosol. Quantification is mean ± SEM
for 3 independent experiments, with budding from endosomes incubated with
complete yeast cytosol set as 1.0. (n.s. = not significant, *: p<0.05, **:p<0.005).

3.2.8 The sst2 PDZ ligand alters sst2 trafficking in somatolactotroph cells
	
  

We hypothesized that the differences we see in intracellular trafficking

between sst2 and sst2 ΔTSI could be more pronounced in cell lines other than
HEK293 cells with differing trafficking machinery. We measured the rate and extent
of internalization and recycling of sst2 and sst2 ΔTSI in GH12C1 cells, a cell model of
somatolactrotroph tumor cells (Fig 14). Interestingly, we found differences in both
the extent of internalization and the rate of recycling between sst2 and sst2 ΔTSI.
Given that sst2 can access numerous pathways to recycle to the plasma membrane,
the specific trafficking machinery present in a given cellular environment dictates
which of those pathways sst2 can access.
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Figure 14. The sst2 PDZ ligand alters recycling in somatolactotroph cells.
A) GH12C1 stably expressing either sst2 or sst2 ΔTSI were treated for various
times with SS14 (100nM). The rate and extent of internalization was measured
using cell surface receptor ELISA. Values were normalized to untreated wells.
Data are shown as the average ± SEM for 3 independent experiments. B)
GH12C1 cells stably expressing either sst2 or sst2 ΔTSI were treated with SS14
(100 nM) for 30 min to induce maximal internalization of receptors. Agonist was
then removed and fresh media containing 100 nM PRL2915 (an sst2 specific
antagonist) was added. Cells were allowed to recover for various times before
fixation and cell surface receptor was normalized to untreated wells. Data are
shown as the average ± SEM for 3 independent experiments. There was no
significant difference in the rate of internalization however there was a
significant difference in the extent. Sst2: 33.7±3.3%, sst2 ΔTSI: 45.5±3.1%,
p=0.0013. While both sst2 and sst2 ΔTSI were able to fully recycle to the
plasma membrane, sst2 ΔTSI recycled significantly faster. t1/2 for sst2: 13.1±2.1
min, sst2 ΔTSI: 5.1±0.7 min., p=0.0003.
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3.2.9 TAT Peptide Design
Given that subtle differences in receptor levels can affect sst2 signaling, we
designed cell permeable peptides to allow us to evaluate changes in signaling in a
signal clonal cell line. These peptides allow us to use the same clonal cells lines to
evaluate how sst2 PDZ ligand-protein interactions affect signaling pathways. The
peptides have two portions, the TAT sequence that allows the peptide to enter the
cell and the 10 C-terminal amino acids to block PDZ interactions.
The sst2 specific peptide (TAT-SST2): GRKKRRQRRRPPQGGGLLNGDLQTSI
The control peptide (TAT-AAA): GRKKRRQRRRPPQGGGLLNGDLQAAA

3.2.10 The sst2 PDZ ligand does not alter G-protein coupling
Using a live, whole cell cAMP assay, we asked if the sst2 PDZ ligand altered
the ability for sst2 to couple to Gi/Go proteins and inhibit cAMP. We showed that
both sst2 ΔTSI and sst2 358T inhibit cAMP accumulation if stimulated with
saturating concentrations of SS14 (Fig 5B). We also asked if a loss of PDZ liganddomain interactions shifts the dose response curve to SS14 as a subtle difference is
G-protein coupling may not be seen with saturating concentrations of SS14. We
found no difference in the dose-response curve to SS14 between cells stably
expressing sst2 or sst2 ΔTSI. We also did not find a difference when PDZ liganddomain interactions were blocked with TAT peptides. This data indicates that the
PDZ ligand is not required for Gi/Go coupling and cAMP inhibition.
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Figure 15. The sst2 PDZ ligand does not affect the inhibition of cAMP. A)
HEK293 cells stably expressing either sst2 or sst2 ΔTSI were transiently
transfected with Promega Glosensor plasmid. Cells were treated with 10µM
NKH477 and various concentrations of SS14 and luminescence was
measured. Data are plotted as the % of maximal luminescence with NKH477
alone. A representative curve of 3 independent experiments is shown. B) Cells
stably expressing both sst2 and the Promega Glosensor plasmid were treated
with either TAT-AAA or TAT-SST2 for 30 min prior to the experiment. Cells
were treated with 10µM NKH477 and various concentrations of SS14 and
luminescence was measured. Data are plotted as the % of maximal
luminescence with NKH477 alone. A representative curve of 3 independent
experiments is shown.
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3.2.11 The sst2 PDZ ligand is not required for potassium channel activation
Sst2 can activate potassium channels leading to membrane
hyperpolarization. This hyperpolarization leads the inhibition of voltage gated
calcium channels and a subsequent decrease in intracellular calcium. The decrease
in intracellular calcium leads to an inhibition of hormone secretion. We asked if the
sst2 PDZ ligand was necessary for the activation of potassium channels. We used
GH12C1, a somatotroph cell line that stably express sst2, and determined if PDZ
interactions changed the membrane hyperpolarization after stimulation with SS14.
Using the FLPR membrane dye, we determine that there is no difference in maximal
membrane hyperpolarization if PDZ interactions are blocked compared to control.
There was also no difference in the time course of activation. This is likely due to
potassium channels being activated by Gi/Go proteins as the activation is PTX
sensitive and we do not see a shift in the dose response curve for cAMP inhibition
when PDZ interactions are blocked.

3.2.12 The sst2 PDZ ligand is not required for calcium inhibition
Activation of sst2 leads to membrane hyperpolarization and a subsequent
inhibition of voltage gated calcium channels. This leads to a decrease in intracellular
calcium and the inhibition of hormone secretion. We asked if blocking PDZ
interactions would alter sst2’s ability to decrease intracellular calcium. Fluo-8 AM is a
fluorescent calcium indicator dye, using this assay we measured relative intracellular
calcium before and after sst2 stimulation. We found no difference in the intracellular
calcium decrease when PDZ interactions are blocked. This is consistent with our
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observations that PDZ interactions do not alter Gi/Go coupling or potassium channel
inhibition. It is possible that the PDZ ligand is not required for the mechanisms that
cause an acute inhibition of hormone secretion.
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Figure 16: The sst2 PDZ ligand is not required for membrane hyperpolarization
or calcium channel inhibition. A) GH12C1 cells stably expressing sst2 were treated
with TAT-AAA or TAT-SST2 for 30min prior to the experiment. Cells were treated
with SS14 (100nM) and membrane polarization was measured with FLIPR
membrane dye. Fluorescence was normalized to untreated wells. Data shown is a
representative experiment. There was no difference in membrane hyperpolarization
between TAT-AAA and TAT-SST2. Data shown is a representative trace from 3
independent experiments. B) GH12C1 cells stably expressing sst2 were treated with
TAT-AAA or TAT-SST2 for 30min prior to the experiment. Cells were treated with
SS14 (100nM) and intracellular calcium was measured with Fluo8. Fluorescence was
normalized to untreated cells. Data shown is a representative experiment. There was
no difference in intracellular calcium inhibition between TAT-AAA and TAT-SST2.
Data shown is a representative trace from 3 independent experiments.
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3.2.13 The sst2 PDZ ligand does not alter ERK/MAPK activation
Depending on the cellular context, sst2 can either activate or inhibit the
ERK/MAPK pathway. In HEK293 cells, sst2 can activate the ERK/MAPK pathway in
both a PTX sensitive and PTX insensitive manner. The activation occurs rapidly,
peaks between 2 and 5 min, and returns to baseline activation levels by 10 min.
Although not as strong of a total activation, the PTX insensitive component also has
the same pattern of activation. As PDZ ligand-domain interactions can affect both
the total activation and the time course of activation of the ERK/MAPK pathway, we
asked if the sst2 PDZ ligand affected sst2’s ability to activate the ERK/MAPK
pathway. Two mechanisms allow for PDZ interactions to affect ERK signaling: one is
the direct scaffolding of receptors to components of the ERK pathway such as
GRB2, and the other is through altered trafficking of receptors which typically alters
the time course of ERK signaling(72, 156). We hypothesized that we would see a
change in the PTX insensitive component, as we do not see changes in the Gi/Go
coupling when PDZ interactions are blocked. HEK293 cells stably expressing sst2
were preincubated with the specific or control TAT peptide, and then stimulated with
SS14 for the times indicated, and placed on ice, and phospho-ERK levels were
determined using western blot. Our data was consistent with the published data,
ERK activation peaked at 2 min and was near baseline by 10 min. Additionally, this
time course was the same for both the PTX sensitive and insensitive component of
activation consistent with the literature. We did not find any difference in either the
extent of activation nor the time course between the control and when PDZ
interactions are blocked. This is consistent with our findings that PDZ interactions
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are not required for Gi/Go coupling. The mechanisms of PTX insensitive ERK
activation have yet to be elucidated but we conclude that PDZ interactions are not
required for this component of activation either.
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Figure 17. The sst2 PDZ ligand is not required for ERK activation. A)
Representative western blot. HEK293 cells stably expressing sst2 were pretreated
with TAT-AAA or TAT-SST2 and then with SS14 (100nM) for various time points.
pERK and total ERK were measured by western blot. B) Quantitation of three
independent experiments of (B). There was no difference in the rate or extent of
ERK activation. C) Representative western blot. HEK293 cells stably expressing
sst2 were treated with pertussis toxin overnight. They were then pretreated with
TAT-AAA or TAT-SST2 and then with SS14 (100nM) for various time points. pERK
and total ERK were measured by western blot. D) Quantitation of three independent
experiments of (C). There was no difference in the rate or extent of ERK activation.
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3.3 Discussion
Endocytic sorting is a major mechanism of GPCR regulation and plays a role
in determining the strength, localization, and specificity of signaling. Many GPCRs
use a complex method of sequence-directed intracellular trafficking that relies on the
receptor being able to interact with various cytoplasmic proteins. This method of
trafficking allows for a receptors’ fate to be determined at multiple points along an
intracellular pathway. Before this study, little was known about the motifs of sst2 that
regulate its endocytic sorting. We have demonstrated that the sst2 PDZ ligand and
10 C-terminal amino acids direct the receptor into various endosomal compartments.
We initially hypothesized that the PDZ ligand was required for sst2 plasma
membrane recycling but surprisingly found that neither the PDZ ligand nor the 10 Cterminal amino acids were required. Thus we assessed whether sst2 undergoes
sequence-directed endocytic sorting, in part determined by the PDZ ligand motif.
Prior studies have demonstrated that sst2 can traffic to the TGN after ligand
stimulation, and then recycle rapidly to the plasma membrane (80, 82). Given that
there are many pathways that receptors can utilize to recycle, we asked if sst2 could
access some of the better described endocytic recycling pathways, including those
regulated by Rab4 and Rab11. Our data was surprising in that wild type sst2
localized to Rab4-positive endosomes during recycling to a greater degree than of
either sst2 mutant, despite the fact that the Rab4 dominant negative did not affect
wild type sst2 recycling. It was similarly interesting in that the dominant negative
Rab11 blocked overall recycling of both sst2 mutants but did not affect wild type sst2
recycling. While initially this data may seem contradictory, it is consistent with the
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idea that wild type sst2 can follow multiple endocytic trafficking pathways depending
on its interaction with distinct cytoplasmic trafficking proteins, and that blocking any
one pathway is not sufficient to prevent receptor recycling. It follows that deletion of
C-terminal residues within sst2 limits the spectrum of trafficking proteins with which
the receptor can interact, thereby uncovering a dependency on Rab4 or Rab11 not
observed with the wild type receptor. Our data also indicates that the PDZ ligand
directs sst2 to the TGN during endocytic trafficking, and that sst2 undergoes
retromer dependent sorting. These data are consistent with the idea that sst2
undergoes sequence-directed endocytic sorting which is regulated at multiple steps.
An outstanding question is if the sst2 PDZ ligand plays a role in signaling.
The two main mechanisms of sst2’s ability to inhibit hormone secretion are
through the acute inhibition of cAMP and the activation of potassium channels
leading to inhibition of calcium channels and a subsequent drop in intracellular
calcium(Fig 2). As both of these mechanisms are dependent upon Gi/Go signaling,
our data is consistent in that if there is no change in Gi/Go coupling when PDZ
interactions are blocked, we should not see any change in either cAMP inhibition of
potassium channel activation. Additionally, this is consistent with the fact that we do
not see a change in intracellular calcium inhibition, as this is dependent on
potassium channel activation and membrane hyperpolarization. This data is also
consistent with our data showing no effect on ERK signaling. The pertussis toxin
sensitive component of ERK signaling is also dependent on Gi/o proteins. However,
how sst2 signals to the ERK/MAPK pathway in a PTX insensitive manner is still
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unknown. Although the mechanism is still unknown, it is unlikely that this signaling is
dependent upon an intact PDZ ligand.
One important caveat to our findings is that PDZ proteins may scaffold sst2 to
ion channels for more efficient signaling. Unfortunately, the time course of activation
of ion channels may be too rapid for us to parse out small changes in the time
course of channel activation using either the membrane polarization or calcium dyes.
A more sensitive method, such as electrophysiology may be required to understand
if there are more subtle changes that occur through protein scaffolding.
An important outstanding question is whether sequence directed trafficking
affects sst2 signaling. Signaling by other GPCRs has been shown to be altered by
subtle changes in receptor trafficking. For example, PTHR1 can traffic through at
least two different pathways depending on PDZ interactions, a rapid recycling
pathway and a slower, retromer-dependent pathway. Importantly, the rapid recycling
pathway is crucial for the effect of PTHR1 on bone development (161). Although it
has yet to be determined if sst2 can signal intracellularly, it’s possible that sst2
traffics through various endocytic pathways to enable different signaling outcomes. It
is further possible that alterations in trafficking-dependent signaling could contribute
to variations in tumor responses to somatostatin analogs. Futures studies will be
necessary to answer these important questions and to continue to fully uncover the
mechanisms that regulate sst2 intracellular trafficking.
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Chapter 4
SHANK3 increases sst2 surface expression in an isoform specific manner

4.1 Introduction
The SHANK family of proteins consists of 3 members, SHANK1, SHANK2,
and SHANK3(92, 134, 139). These proteins are large neuronal scaffolding proteins
that are expressed highly through the central nervous system and in various tissues
throughout the rest of the body(141, 162, 163). They play critical roles in numerous
neuronal processes including actin/cytoskeleton remodeling, AMPA receptor
endocytosis, synapse formation, glutaminergic transmission, and synaptic
plasticity(135, 138, 164). The role of SHANK proteins in disease was first recognized
when the deletion of SHANK3 was determined to be the cause of intellectual
disability in Phelan-McDermind Syndrome(136). Since then, deletions, duplications,
and mutations of all three SHANK proteins have been associated with several
neuronal diseases including autism, schizophrenia, and bipolar disorder(135, 137,
144).
All three proteins have the same basic structure including N-terminal ankyrin
repeats, an SH3 domain, a PDZ domain, a large proline rich region, and a Cterminal sterile alpha motif (SAM domain)(Fig 4). Numerous protein-protein binding
domains allows for SHANK proteins to bind to many other proteins including other
scaffolding proteins, receptors, ion channels, and small GTPases, amongst others to
create macromolecular complexes for rapid and specific signaling(135).
Interestingly, there are many common binding partners amongst the three SHANK
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proteins although the degree of functional overlap of the three proteins has yet to be
determined.
Adding to the complexity, each SHANK protein has multiple promoters and
can be differentially spliced leading to a wide variety of isoforms of all three
proteins(143). There is data demonstrating that specific isoforms have specific
functions, such as the requirement of the SAM domain for synaptic targeting of
SHANK2 and SHANK3, however work still needs to be done to understand tissue
specific isoform expression as well as the functional effect of each isoform(165). The
SAM domain also allows for SHANK3 to scaffold to itself and is thought to be crucial
for organization of the post-synaptic density(166). There is some clinical data
suggesting that certain isoforms play specific signaling roles. Numerous mutations in
SHANK1, 2 and 3 have been implicated in schizophrenia and bipolar disorder.
These mutations are only present in specific isoforms indicating that alternative
isoforms or the other members of the SHANK family cannot compensate for the loss
of function(144).
In this study, we determined that SHANK3 binds to sst2 through a PDZ
ligand-domain interaction similarly to SHANK1 and SHANK2. We asked whether this
interaction was clinically relevant by determining if normal neuroendocrine tissue
such as pituitary expresses the various SHANK family members and if this
expression is altered in neuroendocrine tumors. We found that
while SHANK proteins are expressed in normal neuroendocrine tissues such as the
pituitary, their expression is often altered in an unpredictable pattern in
neuroendocrine tumors. Most importantly, we were able to determine that SHANK3
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expression increases the surface expression of sst2. This function requires the
expression of the full-length isoform of SHANK3, as SHANK3 truncation mutants
were not able to increase the cell surface expression of sst2. These data suggest
that SHANK3 plays an isoform specific role in sst2 membrane expression. Alteration
of SHANK3 expression in neuroendocrine tumors could lead to changes in sst2
expression and therefore affect the tumors response to octreotide.

4.2 Results
4.2.1 SHANK1, SHANK2, and SHANK3 bind to sst2 through the PDZ ligand
SHANK1 and SHANK2 had previously been shown to bind to sst2 through a
PDZ ligand/domain interaction. SHANK1 and 2 were initially identified as sst2
binding partners using a yeast-2-hybrid assay where the sst2 C-terminal tail was the
bait and a rat brain cDNA library was the prey(88). They identified SSTRIP and
CortBP1 as sst2 interactors, which were renamed SHANK1 and SHANK2.
Additionally, they confirmed that it was specifically the PDZ domain of both SHANK1
and SHANK2 that bound to the C-tail of sst2 using GST overlay assays. We were
able to confirm that the PDZ domains of SHANK1 and SHANK2 bind specifically to
sst2 using a biotinylated-peptide pulldown assay. However, SHANK3, which has an
almost identical PDZ domain as SHANK1 and SHANK2, has not been shown to bind
to sst2. We hypothesized that SHANK3 would also bind to sst2 through the PDZ
domain. We found that SHANK1, 2, and 3 all bind specifically to the last 10 amino
acids of sst2 using a biotinylated peptide pulldown assay (Fig 18). None of the
SHANK proteins bound to the peptide where the last three amino acids of sst2 were
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mutated from TSI to AAA to disrupt PDZ binding. These results indicate that all three
SHANK proteins bind to sst2 through a specific PDZ ligand-domain interaction.
These results indicate that sst2 should be able to interact with SHANK protein
isoforms that contain a PDZ domain, although this would have to be confirmed for
each individual isoform. Additionally, some proteins such as mGluR5, can interact
with SHANK3 through both a direct interaction with the PDZ domain and through an
indirect scaffolding intermediate that binds to the proline rich region of
SHANK3(140). We have yet to determine if the interaction with sst2 is solely through
the PDZ domain or could also be through an addition protein.

Figure 18: All three SHANK PDZ domains bind specifically to the PDZ ligand of
sst2.
HEK293 cells were transiently transfected with FLAG tagged SHANK PDZ domains
and the lysates were used in a biotinylated peptide pulldown. The bait was the 10 Cterminal amino acids of sst2 (TSI) or the last 10 but with the final 3 amino acids
mutated to alanines (AAA) to disrupt PDZ binding.
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4.2.2 SHANK protein expression in rat pituitary and pituitary tumor cell lines
SHANK2 and SHANK3 are highly expressed in the cortex and have also been
shown to be expressed in rat pituitary somatotrophs(145). There are numerous
different isoforms of both SHANK2 and SHANK3 and tissue specific expression of
these various isoforms of SHANK proteins have yet to be described. As we did not
know if the pituitary expressed isoforms of SHANK3 that contained a PDZ domain,
we used RT-PCR and specific primers to amplify the PDZ domain of SHANK1, 2, or
3. Rat cortex and pituitary was harvested from Sprague Dawley rats to determine the
tissue specific expression of SHANK proteins. We also examined if two cells line
models of pituitary tumors expressed SHANK isoforms with PDZ domains. GH4C1
cells are a somatolactroph cell line derived from a spontaneous rat pituitary tumor
and secrete both growth hormone and prolactin(167). They express both sst2 and
sst5, which we were able to confirm by RT-PCR (Fig 19A), and respond to SS14 and
SAs. Additionally, we determined if AtT20 cells, a cell model of corticotroph tumors
derived from a mouse tumor, expressed SHANK proteins. AtT20 express both sst2
and sst5, secrete ACTH, and respond to SS and SAs. Cortex was used as a positive
control for both rat and mouse cells lines as all three SHANK proteins are
expressed. Interestingly, only SHANK2 and SHANK3 are expressed in normal rat
pituitary and only SHANK3 in GH4C1 cells, although additional isoforms lacking the
PDZ domains could be present. This is in comparison to AtT20 cells which express
SHANK1 and SHANK2. Unfortunately this assay is limited, as we cannot determine
which specific cell types within the pituitary express different SHANK proteins and is
also limited to only detecting isoforms that contain the PDZ domain.
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Figure 19. SHANK expression in neuroendocrine cell lines. A) SHANK
expression in pituitary tumor cell lines. Primers were designed to amplify the PDZ
domains of the three SHANK proteins by RT-PCR. Expression in tumor cell lines
were compared to rat pituitary. Rat or mouse cortex was used as a positive
control. No reverse transcriptase controls were run but not shown here. Eef2 was
used as a housekeeping control. B) SHANK expression in human gastrointestinal
and pancreatic neuroendocrine tumor cells lines. Primers were designed to
amplify the PDZ domains of the three SHANK proteins by RT-PCR. No reverse
transcriptase controls were run but not shown here. Eef2 was used as a
housekeeping control.
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4.2.3 SHANK expression in human neuroendocrine tumor lines
There are several cell line models of neuroendocrine tumors that are derived
from human tumors although none of these are derived from pituitary tumors.
CNDT2.5 cells are a model of gastrointestinal neuroendocrine tumors(168). These
cells were derived from a liver metastasis from a patient with a primary ileal
carcinoid tumor, secrete serotonin, and express sst2. BON cells are another model
of gastrointestinal NETs, although were derived from a pancreatic carcinoid
tumor(169). The cell type of origin is particularly important for NETs as tumors
derived from different cell types behave differently. Using RT-PCR and primers to
specifically amplify the PDZ domains of the three SHANK proteins, we found that
CNDT2.5 express SHANK1, 2, and 3 whereas BON cells do not express any of the
three SHANK proteins. IMR32 cells, a neuroblastoma cell line, were used as a
positive control as they have been shown to express all three SHANK proteins(142).
SHANK expression in HEK293 cells was also examined (Fig 19B). Again, this assay
is limited as we only looked for isoforms containing the PDZ domain. Additionally,
cells within the diffuse neuroendocrine system are such as small fraction of the total
cells within the gastrointestinal system or pancreas, we do not have the ability to
examine SHANK expression in normal neuroendocrine cells. It is interesting to note
that different types of neuroendocrine cell lines have different SHANK protein
expression. It is possible that sst2’s interaction with SHANK family members or other
PDZ proteins allows for cell type specific regulation by sst2.
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4.2.4 SHANK protein expression is altered in human pituitary tumors
As there is expression of SHANK proteins in pituitary tissue and all three
SHANK proteins can bind to sst2, we hypothesized that SHANK proteins could play
a role in sst2 regulation and response to SAs in human pituitary tumors. We first
asked if SHANK proteins were expressed in normal human pituitary using primers to
amplify the PDZ domains. Interestingly, we found that the expression of SHANK
proteins in normal human pituitary differs from that of rat pituitary. We found that
SHANK1 and 3 are expressed in human whereas SHANK2 and 3 were expressed in
rat. Additionally, we determined the expression of SHANK proteins in four different
types of human pituitary tumors: GH, ACTH, or PRL secreting along with nonfunctioning adenomas. Although we could not correlate our data with the response
to SAs, we found that pituitary tumors have variable expression of all three SHANK
proteins (Table 2). The alteration of the various SHANK proteins in pituitary tumor
could potentially effect regulation of sst2.
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Table 2: SHANK expression in human pituitary samples. SHANK and sst2
expression in human pituitary tumor samples was determined by PCR. Primers
were designed to amplify the PDZ domains of the various SHANK proteins.
Results were compared to normal human pituitary.
	
  
4.2.5 SHANK3 increases plasma membrane expression of sst2.
We have shown that the loss of the PDZ ligand or 10 C-terminal amino acids
decreases the amount of sst2 present on the plasma membrane (Fig 5C).
Interestingly, we found that co-expressing sst2 and SHANK3, increases the amount
of sst2 present on the plasma membrane. This effect is also specific for SHANK3, as
co-transfecting sst2 and SHANK1 did not increase sst2 surface expression(Fig 20A).
This effect is also independent of the PDZ ligand of sst2 as expression of SHANK3
increased the plasma membrane expression of both sst2 ΔTSI and sst2 358T (Fig
20B). It is possible that SHANK3 can bind to sst2 through additional sites.
Additionally, it is possible that the effect on plasma membrane expression does not
require direct binding. Expression of SHANK3 could allow for increased expression
of sst2 at the plasma membrane either through indirect binding to sst2 through an
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intermediate such as cortactin or through a mechanism such as altering endosomal
dynamics.
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Figure 20. SHANK3 increases cell surface expression of sst2. A) HEK293 cells
were co-transfected with HA tagged sst2 and either SHANK3, SHANK1, or an empty
vector used as a control. Receptor cell surface expression was measured by ELISA
and normalized to the surface expression of sst2 with the vector control. Data are
the average± SEM of three independent experiments. B) SHANK3 increases cell
surface expression independent of the PDZ ligand. HEK293 cells were cotransfected SHANK3 and HA tagged sst2, sst2 ΔTSI, or sst2 358T. Receptor cell
surface expression was measured by ELISA and normalized to the surface
expression of sst2 with the vector control. (n.s.=not significant, *=p<0.05,
***=p<0.0005).
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4.2.6 The SAM domain of SHANK3 is required for increased expression of sst2
We created two truncation mutants of SHANK3 to understand if the full-length
isoform of SHANK3 or certain binding domains are required for the effect on sst2
plasma membrane expression. The SAM domain of SHANK3 has been shown to be
required for synaptic targeting and SHANK3 isoforms that lack the SAM domain
often are localized in the nucleus(165). We hypothesized that the SAM domain was
required for the effect of surface expression of sst2. One truncation mutant lacked
just the SAM domain and the second lacked both the SAM domain and the cortactin
binding region in the proline rich region(Fig 21A). The cortactin binding domain was
removed as binding to cortactin is one of the major ways the SHANK3 organizes
protein-complexes. Cortactin allows SHANK3 to interact with the actin-cytoskeleton
and has functions in SHANK3 regulation of protein trafficking leading us to
hypothesize that cortactin could play a role in sst2 cell surface expression(166). We
also tested if the PDZ domain was sufficient to increase cell surface expression. We
found that co-expressing the PDZ domain of SHANK3 was not sufficient to increase
cell surface expression of sst2 (Fig 21C). Interestingly, we found that only the full
length SHANK3 construct increases sst2 plasma membrane expression. Neither
SHANK3 1448T, nor SHANK3 1334T was able to increase sst2 expression
compared to co-expressing an empty GFP construct (Fig 21D).
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Figure 21. The SAM domain is required for increased cell surface of sst2 by
SHANK3. A) Cartoon depicting the protein-protein binding domains present in the
various SHANK clones. B) Western showing expression of the three SHANK clones.
C) HEK293 cells were co-transfected with sst2 and a clone expressing only the PDZ
domain of SHANK3 or an empty vector control. Receptor cell surface expression
was measured by ELISA and normalized to the surface expression of sst2 with the
vector control. Data are the average ± SEM of three independent experiments. D)
HEK293 cells were co-transfected with sst2 and a full length SHANK3, a truncation
mutant lacking the SAM domain (1448T), or a truncation mutant lacking the SAM
domain and part of the proline-rich region. Receptor cell surface expression was
measured by ELISA and normalized to the surface expression of sst2 with the vector
control. Data are the average ± SEM of three independent experiments. (n.s.=not
significant, *=p<0.05, ***=p<0.0005).
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4.2.7 SHANK3 does not alter internalization of sst2
As we hypothesized that SHANK3 plays a role in sst2 trafficking, we asked if
SHANK3 would alter the rate or extent of internalization of sst2 after stimulation with
agonist. We transfected cells with sst2 and SHANK3 or an empty GFP vector as a
control. Transfections were titrated to have the same amount of SHANK3 and GFP
but to match sst2 surface expression. We used a cell surface ELISA to measure
both the rate and extent of sst2 internalization after stimulation with SS14 and found
no difference in either (Fig 22A). This indicates that SHANK3 is not tethering the
receptor at the membrane and increasing cell surface expression in that manner. We
also tested if the PDZ domain of SHANK3 alone had an effect on the extent of sst2
internalization (Fig 22B). We did not find an effect, which is consistent with our data
indicating that the PDZ domain of SHANK3 does not alter surface expression and
the full length SHANK3 protein does not alter the rate or extent of internalization of
sst2.
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Figure 22: Overexpression of SHANK3 does not alter sst2 internalization. A)
HEK293 cells were transiently transfected with sst2 and either an empty GFP vector
or GFP-SHANK3. Cells were treated with SS14 (100nM) for the times indicated and
receptor cell surface expression was determined by ELISA. Data are the mean ±
SEM of three independent experiments. There is no difference in the rate or extent
of internalization between the control and SHANK3 overexpression groups as
determined by sum of squares F-test. B) HEK293 cells were co-transfected with sst2
and a clone only expressing the PDZ domain of SHANK3 or an empty vector as a
control. Cells were treated with SS14 (100nM) for 30min and cell surface expression
was determined by ELISA and compared to untreated cells. (n.s. = not significant)

4.2.8 The SAM domain alters subcellular localization of SHANK3
We sought to further understand how SHANK3 alters sst2 surface
expression. We began by determining the subcellular localization of the full length
SHANK3 constructs versus the two truncation mutants. We found that both the
truncation mutants were localized in the nucleus where the full-length SHANK3
construct clustered in cytoplasmic puncta. This is consistent with the literature
however it is not know what vesicles full length SHANK3 is localized in. Importantly,
none of the SHANK3 constructs are localized at the plasma membrane at steady
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state indicating that SHANK3 likely plays a role in sst2 anterograde or retrograde
trafficking versus playing a role in stabilizing the receptor at the membrane.

Figure 23. Localization of SHANK truncation mutants. GFP tagged SHANK
truncation mutants were co-transfected with sst2 into HEK293and stained for
immunofluorescence. Cells were imaged by widefield fluorescence imaging with a
40x objective.

	
  

91	
  

4.2.9 Rat pituitary expresses alternative isoforms of SHANK3
Given that only the full-length isoform of SHANK3 increased cell surface
expression of sst2 and not the truncation mutants, we asked if the full length
SHANK3 isoform was present in pituitary tissue by western blot. We used two
different commercially available antibodies that detect various regions of SHANK3.
The first is targeted towards the N-terminal and detects the SH3 and PDZ domains.
The second antibody detects the C-terminal region and was raised against a large
portion of the proline-rich region. Rat cortex and pituitary were harvested from
Sprague Dawley rats to determine SHANK protein expression. A SHANK2 antibody
was used as a control, as whole rat pituitary extracts have been shown to express
SHANK2. Interesting, we found a different pattern of expression in the three protein
extracts using the N-terminal and C-terminal SHANK3 antibodies indicating that
there are multiple protein isoforms of SHANK3 present in the pituitary. Additionally,
the pattern of expression differs from that of the cortex and from GH4C1 cells, a rat
somatotroph cell line. This finding is of particular significance given that the fulllength isoform of SHANK3 was required to increase cell surface expression of sst2.

Figure 24: SHANK3 expression in rat cortex, pituitary, and GH4C1 cells. A) Rat
cortex, rat pituitary, and GH4C1 lysates were probed for SHANK3 expression using
two different antibodies. The N-terminal SHANK3 antibody targets the PDZ domain
and the C-terminal SHANK3 antibody was raised to a portion of the proline-rich
region. Lysates were also probed for SHANK2 using an antibody targeting the PDZ
domain. B) Specificity of SHANK antibodies. HEK293 cells were transfected with
GFP tagged SHANK1, SHANK2, or SHANK3 clones and probed with the antibodies
listed.
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4.3 Discussion
SHANK1 and SHANK2 have been shown to bind to sst2 through their PDZ
domains(88-90). They were initially identified as sst2 binding proteins using a yeast2-hybrid screen with the C-terminal of sst2 as bait and a human brain cDNA library.
Although the group that identified these binding partners were not able to find a
function for this protein-protein binding, they concluded that SHANK2 is recruited to
the plasma membrane in sst2 expressing cells after stimulation with SS14(90). We
were able to show that SHANK3 also interacts with sst2 through a PDZ liganddomain interaction. It is possible that sst2 interacts with SHANK3 indirectly as well
although we were not able to determine this. Other receptors, such as mGluR5, can
interact with SHANK3 both directly through a PDZ ligand-domain interaction and
indirectly through binding to cortactin(166).
It is likely that SHANK1, SHANK2, and SHANK3 have different effects on sst2
regulation and signaling, allowing sst2 to exert context specific effects. Interestingly,
SHANK2 and SHANK3 were also identified in rat pituitary cells, specifically
somatotrophs where sst2 is also highly expressed, indicating that SHANK proteins
likely play a role in sst2 regulation in the pituitary(145). An important outstanding
question is which isoforms of SHANK2 and SHANK3 are present in the pituitary, as
this would determine both the possibility for these proteins to interact with sst2 in a
PDZ dependent manner, and would affect the specific regulatory effects they had on
sst2. Of note, we determined that SHANK expression varies between rat and human
and while SHANK2 and SHANK3 are expressed in rat pituitary, SHANK1 and
SHANK3 are present in human pituitary tissue. Importantly, we determined that the
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expression of SHANK proteins varies between normal tissue and neuroendocrine
tumors. Both secretory and non-functioning pituitary tumors lost or gained various
SHANK proteins. The potential effects on sst2 regulation and signaling are
numerous and much work needs to be done to understand the functional effects of
the three different SHANK family members on sst2.
How PDZ proteins influence sst2 regulation, trafficking, and signaling is an
important and outstanding question. Before we began this study, SHANK1 and
SHANK2 had been shown to bind to sst2 through a PDZ ligand-domain interaction,
however nothing was known about the functional role of this binding. Co-expression
of full length SHANK3 and sst2 leads to increased cell surface expression of sst2.
This effect required the full-length isoform of SHANK3 and was abolished when the
SAM domain of SHANK3 was removed. This difference is likely due to the nuclear
localization of the SHANK3 isoforms lacking a SAM domain, they likely cannot
interact with sst2 in either the cytoplasm or at the plasma membrane. The
mechanism through which SHANK3 alters sst2 surface expression is an outstanding
question. We hypothesize that SHANK3 increases surface expression through
regulating anterograde trafficking of sst2. We found that SHANK3 expression did not
alter the rate or extent of sst2 internalization. Additionally, sst2 is stable at the cell
membrane in the absence of agonist and SHANK3 is found in discrete vesicles at
steady state. This indicates that SHANK3 is not altering either agonist driven or
constitutive internalization pointing to a role for SHANK3 in anterograde transport of
sst2 to the cell membrane. Overall, our data indicates an important role for SHANK3
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in cell surface expression of sst2 in neuroendocrine tissues and tumors likely playing
an important role in tumor response to octreotide.
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Chapter 5
Discussion and Future Directions

5.1 Somatostatin Analogs and Neuroendocrine Tumors
Understanding how sst2 exerts its effects in cells is crucial to not only
understand its physiological role but also its role in the treatment of neuroendocrine
tumors. Somatostatin analogs have been an effective tool for the diagnosis and
treatment of NETs. First, SAs are the most effective treatment available to treat
hormone hyper-secretion from a wide variety of tumor types. Hormone secretion can
cause problems that range from uncomfortable to debilitating to deadly(23).
Activation of sst2 in these tumor types leads to a decrease in cAMP and to the
activation of potassium and calcium channels to decrease acute hormone
secretion(1). Secondly, SAs have been shown to control tumor growth. While
numerous reports showing the inhibition of tumor growth have been described since
the clinical introduction of octreotide, only recently do we have robust clinical data
demonstrating this effect independent from the effects on hormone secretion(44,
61). Additionally, the anti-secretion and anti-tumor effects are not always linked even
in functional NETs. This indicates that the pathways that sst2 regulates for hormone
secretion and those governing tumor growth are distinct in certain cell populations.
Thirdly, radiolabeled SAs are used to both to both identify and ablate NETs. Given
the wide clinical use of SAs, understanding cell type specific effects of sst2 has
become increasingly important(50). While the mechanism leading to an acute
decrease in hormone secretion has been well described, the mechanisms governing
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long-term reductions in hormone synthesis, tumor growth, and drug resistance are
all still poorly understood. As there are limited additional treatment options for NETs,
especially to control hormone hyper-secretion, increasing our understanding of how
sst2 exerts its function is an important clinical and basic science question.
Perhaps the most important outstanding question is the mechanism
governing NET resistance to SAs. There are two general patterns of resistance to
SAs seen in NET. Pituitary tumors, particularly GH-secreting tumors, tend to either
initially respond or are resistance to SAs. This differs from the pattern seen in GI and
pancreatic NETs that tend to lose their response over time(16). While many
hypotheses have been developed to explain tumor resistance to SAs, none can fully
explain tumor resistance. Originally it was thought that resistance tumors must lack
expression of sst2, however this turned out not to be the case. As sequencing
methods improved, others looked into the possibility of mutations within the receptor
leading to a lack of drug response. This turned out to be relatively uncommon and
could not account for almost 50% of pituitary tumors not responding to SAs. Given
that neither loss of the receptor nor mutations account for the resistance to SAs
observed in pituitary tumors, the current hypothesis is that sst2 cannot engage with
its downstream machinery to exert its anti-secretion effects(2). Numerous reports
exist showing a decrease in hormone secretion without an anti-tumor effect and
more recently SAs have been used in non-secretory NETs. The combination of
clinical and basic science data indicates that sst2 exerts cell type specific effects
through numerous pathways that have yet to be fully described. Understanding
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these different pathways is crucial for to understand the different effects seen in both
different tumor types and within the same tumor type.

5.2 Sst2 Trafficking and Signaling
GPCRs use numerous mechanisms to exert cell specific effects even while
acting on common pathways. One mechanism that has been shown to be
increasingly important not only for GPCRs but numerous receptors, ion channels,
kinases, and other proteins is specific spatial-temporal signaling. GPCRs can act in
protein complexes at specific times and cellular locations after activation to generate
highly specific signals. These signals depend both on a receptor’s ability to bind to
and interact with specific protein complexes and to be on the correct intracellular
pathway. PDZ ligands are highly flexible protein-protein binding domains allowing for
receptors to bind to numerous PDZ domain-containing proteins. Many of these PDZ
domain-containing proteins are large scaffolding proteins that allow for the
development of large protein complexes. Before this study, there were three known
PDZ binding partners for sst2, however nothing was known about the function of the
sst2 PDZ ligand.
While there are numerous outstanding questions about the role of PDZ
ligand-domain interactions in the regulation of sst2, we have shown that the PDZ
ligand acts as a crucial intracellular trafficking signal, governing the specific route
that sst2 takes through the cell. Sst2 requires a specific set of protein-protein binding
partners to traffic through the cell and uses alternative routes to return to the cell
surface if those binding partners are disrupted. Interestingly, sst2 does not need a
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PDZ ligand or its 10 C-terminal amino acids to efficiently recycle to the plasma
membrane after internalization but we have found that the C-terminal mutants can
access different recycling pathways.
An important outstanding question is why sst2 can access these different
pathways. One potential explanation is various recycling pathways are necessary to
exert specific signaling effects. For example, PTHR1 can recycle through both a
slower recycling pathway through the TGN and a rapid recycling pathway. The rapid
recycling pathway is necessary for PTHR1 to exert its effects on bone
development(74, 161). While signaling through Gi/o proteins is well described for
sst2, it is likely that sst2 affects a range of other signaling pathways that have yet to
be described. Further characterization of these pathways is going to be necessary
before understanding the potential signaling effects. Whether sst2 signals
intracellularly is another outstanding question. Receptors can signal both at the
plasma membrane and from endosomes through both G-proteins and other
signaling pathways such as β-arrestin(170). Teasing out membrane signaling from
intracellular signaling is a difficult task given the burst of signaling that is generated
at the plasma membrane versus the more subtle signaling that occurs along the
intracellular trafficking pathway. This requires a careful selection of the signaling
output used along with a specific assay design to distinguish the location of signal
generation. Common outputs used to gauge intracellular signaling for GPCRs
include cAMP accumulation and ERK phosphorylation as these tend to be easy to
measure and have been demonstrated to be generated both at the membrane and
from endosomes for GPCRs. Sst2’s role as an inhibitory receptor adds a significant
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challenge to studying and understanding the receptor’s signaling. This requires
interpretation of both the dynamics of the stimulant and sst2’s inhibitory effect
making determining the location of signaling more difficult.
Another potential explanation for sst2’s ability to access different recycling
pathways is to allow for a population of receptors to undergo resensitization. This
pathway could be crucial for receptors to be fully functional after returning to the
plasma membrane. Numerous additional questions remain such as which trafficking
proteins are sorting sst2 into these various pathways and are modifications to sst2
required.

5.3 SHANK protein regulation of sst2
	
  

How SHANK proteins affect the trafficking, signaling, and regulation of sst2 is

still an important and outstanding question. We were able to confirm that the PDZ
domains of SHANK1 and SHANK2 can bind to sst2 and we showed that sst2 binds
to the SHANK3 PDZ domain as well. We were also able to show that SHANK3
expression increases cell surface expression of sst2. Interestingly this requires the
full-length isoform of SHANK3 but is not dependent on the PDZ ligand of sst2. Both
the mechanism of the effect and why it is PDZ ligand independent are both
interesting and worthwhile questions to pursue in the future. We hypothesize that
SHANK3 could be acting at one of several different steps of sst2 regulation. The first
possibility is that SHANK3 could be altering sst2 anterograde trafficking. SHANK3
could act as a chaperone from the endoplasmic reticulum or the trans-golgi network
to help shuttle sst2 to the membrane. It could also potentially affect endosomal
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dynamics allowing for greater numbers of sst2 receptors to reach the plasma
membrane. Another possibility is that SHANK3 helps stabilize sst2 at the plasma
membrane or inhibits constitutive internalization. This possibility is less likely given
that SHANK3 is not located at the plasma membrane at steady state. Additionally,
sst2 is stable at the membrane in the absence of ligand. The final possibility is that
SHANK3 alters sst2 recycling to allow for more receptors to return to the plasma
membrane. As sst2 recycles almost fully and the increase in cell surface receptor is
seen at steady state, an alteration in recycling is less likely. Going through these
various possibilities lead us to hypothesize that SHANK3 is most likely playing a role
in anterograde trafficking. As little is known about sst2’s anterograde trafficking,
much work will need to be done to understand which proteins are involved in the
export of sst2 to the plasma membrane and how SHANK3 is involved in this
process.
Our data also indicates that the full-length isoform of SHANK3 is required for
increased sst2 cell surface expression. This leads to the question of how the other
two SHANK proteins, SHANK1 and SHANK2, regulate sst2 and if the various
isoforms play different roles in sst2 trafficking, signaling, and regulation.
Interestingly, we did not find that the full-length isoform of SHANK3 is expressed in
the pituitary. However, SHANK2 and SHANK3 have been shown to be expressed in
somatolactotrophes and we found that additional shorter bands were detected in the
pituitary by western blot(145). A future experiment would be to characterize the
isoforms present in the pituitary either by rapid amplification of cDNA ends (5’
RACE) or another method. Understanding which isoforms are present in the pituitary
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is crucial to then understand how these various isoforms interact with sst2 and what
their role in sst2 regulation may be. Additionally, it would be worthwhile to
understand how the interactions of sst2 and SHANK proteins affect sst2 localization
and the synapse and sst2 modulation of neuronal signaling. Overall, there is a great
deal of work left to be done to understand the interaction between sst2 and the
various SHANK proteins.

5.4 Summary
	
  

Sst2 plays a crucial role in the treatment of neuroendocrine tumors and

overcoming resistance to somatostatin analogs will be a large clinical advance.
Understanding how sst2 exerts cell and context specific effects will allow us to better
understand tumor responses to somatostatin analogs. Before this study, little was
known about the intracellular trafficking of sst2 and the motifs that regulate that
trafficking. We have shown that sst2 traffics from early to late endosomes, and is
sorted in a retromer dependent manner from the late endosome to the TGN. We
have also shown that sst2 can recycle to the plasma membrane through multiple
different pathways depending upon its ability to bind to sorting proteins through
binding either the last three or ten amino acids of the C-terminal tail. We have shown
the SHANK3, a PDZ domain protein, can increase surface expression of sst2.
Despite these discoveries, numerous questions remain. More studies will need to be
done to understand which proteins are involved in sorting sst2 at each step and what
the consequences of undergoing sequence dependent sorting is for sst2.
Additionally, numerous questions remain as to how the SHANK family of proteins
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interacts with and affects sst2 regulation. Better understanding these interactions will
help us to understand the consequences of altered expression of SHANK proteins
and other sst2 interacting proteins in tumor cells. Addressing these questions and
continuing to elucidate mechanisms of sst2 regulation will allow us to improve
treatments for NETs in the future.
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